OXAZOLO [5 , 4 -B] PYRIDIN- 5 -YL COMPOUNDS AND THEIR USE FOR
THE TREATMENT OF CANCER
The p38 MAP kinase is a mitogen-activated protein (MAP) kinase that
belongs to the serine/threonine kinase superfamily. This kinase is activated by
5 extracellular stresses such as heat, UV light, and osmotic stress, as well as by
inflammatory stimuli such as lipopolysaccharides. When activated, p38 MAP kinase
phosphorylates intracellular protein substrates that regulate the biosynthesis of the
pro-inflammatory cytokines tumor necrosis factor a (TNFa), interleukin- 1(IL- ),
interleukin 6 (IL-6) and interleukin 8 (IL-8). These cytokines are implicated in the
0 pathology of a number of chronic inflammatory disorders. Chronic inflammation is a
key risk factor for cancer development. For example, the p38 MAP kinase pathway is
a target of the Kaposi's Sarcoma associated Herpes Virus (KSHV) which results in
chronic inflammation and development of sarcoma. In addition, the cytokines
regulated by p38 MAP kinase, such as IL-8, have been implicated in driving
5 angiogenesis associated with tumor growth. The phosphorylated form of mitogenactivated
protein kinase-protein kinase 2 (or pMAPKAPK2) is also a kinase in the
p38 MAP kinase pathway and can be directly activated by p38 MAP kinase. Mouse
knockout studies of MAPKAPK2 show a reduction in cytokine production suggesting
MAPKAPK2 can be a key regulator of the inflammatory response and can also be a
0 potential target for anti-inflammatory and/or cancer therapy (WO2005 120509).
Azabenzothiazolyl p38 MAP kinase inhibitors (for example, WO2007016392)
have been disclosed in the art for the treatment of anti-inflammatory diseases.
Additionally, azabenzimidazolyl p38 MAP kinase inhibitors (for example,
WO2005075478) have been disclosed in the art for the treatment of cancer. Further,
5 WO2009 17822 discloses imidazolyl oxazoles and oxazolo[4,5-b]pyridine-6-yls useful
as inhibitors of PI3 kinase.
However, certain p38 MAP kinase inhibitors or cytokine inhibitors may have
bioavailability and absorption problems that limit their in vivo effects and therapeutic
use. Additionally, certain p38 MAP kinase inhibitors may present adverse
0 toxicological effects (especially GI toxicity) to a patient and harbor risks of patient
drug-drug interactions. Therefore, a need exists for alternative cytokine suppressive
drugs. Preferably such compounds are capable of inhibiting p38 MAP kinase with
improved potency and greater bioavailability. Preferably such compounds also have
an improved toxicology profile (especially GI toxicity) and decreased risk of patient
drug-drug interactions.
The present invention provides novel oxazolo[5,4-b]pyridin-5-yl compounds
that may have clinical use as a single agent for treatment of cancer and particularly
ovarian cancer and/or multiple myeloma. Further, the present invention provides
novel oxazolo[5,4-b]pyridin-5-yl compounds that may have clinical use in
combination with another therapeutic agent such as sunitinib for treatment of cancer
and particularly renal cancer. Additionally, compounds of the present invention are
potent p38 MAP kinase inhibitors (38, 38, and p38 MAP kinase signaling in
cancer cells) and may have an improved toxicology profile (especially GI toxicity)
and decreased risk of patient drug-drug interactions compared to certain previously
known p38 MAP kinase inhibitors.
The present invention provides compounds of Formula I :
Formula I
where:
X is methoxyethyl or ethoxymethyl;
Q is cyclopropyl, 2-methyl-propanol-2-yl, 3-methyloxetan-3-yl, 1-
hydroxymethyl- 1-cyclopropyl;
or a pharmaceutically acceptable salt thereof.
The present invention also provides crystalline 2-[5-(2,4-difluorophenyl)-4-[2-
[[(lS)-3-methoxy-l-methyl-propyl]amino]oxazolo[5,4-b]pyridin-5-yl]-lH-imidazol-
2-yl]-2-methyl-propan-l-ol characterized by the X-ray powder diffraction pattern (Cu
radiation, = 1.54060 A) comprising a peak at 15.06, and one or more peaks at 19.94,
10.31, and 20.78 (2+/- 0.20) .
The present invention also provides crystalline 2-[5-(2,4-difluorophenyl)-4-[2-
[[(lS)-3-methoxy-l-methyl-propyl]amino]oxazolo[5,4-b]pyridin-5-yl]-lH-imidazol-
2-yl]-2-methyl-propan-l-ol characterized by the X-ray powder diffraction pattern (Cu
radiation, = 1.54060 A) comprising a peak at 13.73, and one or more peaks at 16.54,
22.87, and 18.57 (2+/- 0.20) .
The present invention provides a compound which is 2-[5-(2,4-
difluorophenyl)-4-[2-[[(lS)-3-methoxy-l-methyl-propyl]amino]oxazolo[5,4-
b]pyridin-5-yl]-lH-imidazol-2-yl]-2-methyl-propan-l-ol, or a pharmaceutically
acceptable salt thereof.
The present invention provides a compound which is 5-[2-cyclopropyl-5-(2,4-
difluorophenyl)- lH-imidazol-4-yl]-N-[(l S)-3-methoxy- 1-methyl-propyl]oxazolo[5,4-
b]pyridin-2-amine, or a pharmaceutically acceptable salt thereof.
The present invention provides a compound which is 5-[5-(2,4-
difluorophenyl)-2-(3 -methyloxetan-3 -yl)- 1H-imidazol-4-yl] -N-[( 1S)-3 -methoxy- 1-
methyl-propyl]oxazolo[5,4-b]pyridin-2-amine, or a pharmaceutically acceptable salt
thereof.
The present invention provides a compound which is [l-[5-(2,4-
difluorophenyl)-4-[2-[[(lS)-2-ethoxy-l-methyl-ethyl]amino]oxazolo[5,4-b]pyridin-5-
yl]-lH-imidazol-2-yl]cyclopropyl]methanol, or a pharmaceutically acceptable salt
thereof.
The present invention provides a method of treating ovarian cancer in a
mammal comprising administering to a mammal in need of such treatment an
effective amount of a compound or salt of the present invention.
The present invention provides a method of treating multiple myeloma in a
mammal comprising administering to a mammal in need of such treatment an
effective amount of a compound or salt of the present invention.
The present invention provides a method of treating cancer, in particularly
renal cancer, in a mammal comprising administering to a mammal in need of such
treatment an effective amount of a compound or salt of the present invention in
simultaneous, separate or sequential combination with sunitinib.
This invention also provides pharmaceutical compositions comprising a
compound or salt of the present invention in combination with one or more
pharmaceutically acceptable carriers, diluents, or excipients. In a particular
embodiment the composition further comprises one or more other therapeutic agents.
More particularly, the other therapeutic agent is sunitinib.
This invention also provides a compound or salt of the present invention for
use in therapy. The invention also provides a compound or salt of the present
invention for use in the treatment of cancer. Additionally, this invention provides use
of a compound or salt of the present invention in the manufacture of a medicament for
treating cancer. Additionally, this invention provides for use of a compound or salt of
the present invention for use in the treatment of cancer. In particular this cancer is
ovarian cancer. Additionally, this cancer is multiple myleoma.
This invention also provides a compound of the present invention, or a
pharmaceutically acceptable salt thereof, and sunitinib as a combined preparation for
simultaneous, separate or sequential use in therapy.
The invention also provides sunitinib for use in simultaneous, separate or
sequential combination with a compound of the present invention, or
pharmaceutically acceptable salt thereof, in the treatment of cancer. In the alternative
the invention provides a compound of the present invention, or pharmaceutically
acceptable salt thereof, for use in simultaneous, separate or sequential combination
with sunitinib in the treatment of cancer. More particularly, the cancer is renal
cancer.
It will be understood by the skilled reader that compounds of Formula I are
capable of forming salts. The compounds of the present invention contain basic
heterocycles, and accordingly react with any of a number of inorganic and organic
acids to form pharmaceutically acceptable acid addition salts. Such pharmaceutically
acceptable acid addition salts and common methodology for preparing them are well
known in the art. See, e.g., P. Stahl, et a , HANDBOOK OF PHARMACEUTICAL
SALTS: PROPERTIES, SELECTION AND USE, (VCHA/Wiley-VCH, 2008); S.M.
Berge, et a , "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, Vol 66,
No. 1, January 1977.
The skilled artisan will appreciate that compounds of the present invention
contain at least one chiral center. The present invention contemplates all individual
enantiomers or diastereomers, as well as mixtures of the enantiomers and
diastereomers of said compounds including racemates. It is preferred that compounds
of the present invention containing at least one chiral center exist as single
enantiomers or diastereomers. The single enantiomers or diastereomers may be
prepared beginning with chiral reagents or by stereoselective or stereospecific
synthetic techniques. Alternatively, the single enantiomers or diastereomers may be
isolated from mixtures by standard chiral chromatographic or crystallization
techniques.
Sunitinib, marketed as SUTENT®, is an oral, small-molecule, multi-targeted
receptor tyrosine kinase inhibitor that was approved by the FDA for the treatment of
renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumors. Sunitinib
is disclosed in WO200160814.
Scheme I
Preparation of compounds of Formula I, wherein R is cyclopropyl or 3-
methyloxetan-3-y
Formula I
(A)
Ortho-hydroxypyridyl-3 -amines (A) are treated with isothiocyanates (B),
which may be racemic or a single enantiomer, in ethanol with heating. During
heating and periodically, excess of an N, N'-disubstituted-carbodiimide is added to
remove hydrogen sulfide. For example, N, N'-dicyclohexyl-carboiimide, N, N'-
diisopropyl-carbodiimide, or l-ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride may be used. The synthesis of isothiocyanates (B), which may be
racemic or a single enantiomer, are described in the preparations below.
Scheme II
Preparation of compounds of Formula I, wherein R is methyl 2-methylpropanecarboxyate-
2-yl or methyl cyclopropane carboxylate-l-yl; X is as defined
above.
Formula I
5-(lH-imidazol-4-yl)oxazolo[5,4-b]pyridines (C) are reduced with lithium
borohydride in ether to give compounds of Formula I . The intermediates (C) are
similarly prepared from the corresponding hydroxypyridyl-3 -amines (A) (Scheme I),
wherein R is methyl 2-methyl-propanecarboxyate-2-yl or methyl cyclopropane
carboxylate-l-yl with isothiocyanates (B), as in Scheme I .
Scheme III
Synthesis of intermediates (A), wherein R is methyl 2-methylpropanecarboxyate-
2-yl, methyl cyclopropane carboxylate-l-yl, cyclopropyl, or 3-
methyloxetan-3 -yl
6-(lH-Imidazol-4-yl)-3-nitro-pyridin-2-amine (D) undergoes functional group
manipulations on the pyridine ring involving diazotization of the 2-pyridyl amine
group followed by water quench, then hydrogenation of the 3-pyridyl nitro group to
give intermediates (A).
Scheme IV
Synthesis of intermediates (D), wherein R is as defined in Scheme III.
(F) (E)
Intermediates (D) are prepared from l-(6-amino-5-nitro-2-pyridyl)-2-(2,4-
difluorophenyl)ethane- 1,2-dione (F) and the known aldehydes (E) by heating in
dioxane with ammonium acetate. The synthesis of intermediate (F) is described in the
preparations below.
The compounds of the present invention are prepared essentially as illustrated
in the Schemes, Preparations and Examples below. The reagents and starting
materials are readily available to one of ordinary skill in the art or may be made by
procedures which are selected from standard techniques of organic and heterocyclic
chemistry, techniques which are analogous to the syntheses of known structurally
similar compounds, and the procedures described in the Examples below, including
any novel procedures. It should be understood that the Preparations and Examples are
set forth by way of illustration and not limitation, and that various modifications may
be made by one of ordinary skill in the art.
The naming of the following Preparations and Examples is generally done
using the IUPAC naming feature in SYMYX® Draw version 3.2.NET.
Preparation 1
tert-Butyl (3S)-3 -[benzyl-[( 1S)- 1-phenylethyl]amino]butanoate
0 2t-Bu
Preparations 1 and 2 have been described in WO 2006/076595 for the R,R
enantiomer. See also Davies, S. G. and Ichihara, O. Tetrahedron:Asymmetry 1991, 2,
183-186 for asymmetric synthesis of 3-aminobutanoates from (E)-but-2-enoates
(crotonates).
(lS)-N-Benzyl-l-phenyl-ethanamine (28.53 g, 135 mmol), is dissolved in
anhydrous tetrahydrofuran (THF) and the solution is cooled to 0 °C under an argon
atmosphere. N-Butyllithium (2.5 M in hexanes, 54 mL, 135 mmol) is added dropwise
over 30 min. The reaction mixture is stirred for 20 min at 0 °C and then cooled to -78
°C. A solution of tert-butyl (E)-but-2-enoate (10 g, 70.32 mmol) in anhydrous THF
(75 mL) is added to the reaction mixture over 20 min. After 75 min, the reaction is
quenched by adding a saturated solution of NH4C 1 (175 mL) and saturated aqueous
NaCl (brine, 100 mL). The layers are separated and the aqueous layer is extracted
with diethyl ether (2 x 125 mL). The combined organic layers are dried over
anhydrous MgS0 4, filtered, and concentrated to afford a yellow oil. The crude
product is dissolved in hexanes (250 mL) and washed with a 10% aqueous citric acid
solution (3 x 75 mL). The organic layer is dried over MgSC^, filtered, and
concentrated to afford the title compound as a yellow oil (24.12 g, 97%). LC-ES/MS
m/z 354 (M+l).
Preparation 2
(3S)-3-[Benzyl-[(lS)-l-phenylethyl]amino]butan-l-ol
-Butyl (3S)-3- [benzyl- [(lS)-l-phenylethyl]amino]butanoate (24 g, 67.9
mmol) is dissolved in anhydrous THF (237 mL) and cooled to 0 °C under an argon
atmosphere. 1M Lithium aluminum hydride in THF (237 mL, 237 mmol) is added
dropwise over 10 min. The reaction mixture is stirred at 0 °C for 1 h and then at 60
°C for 1 h. The mixture is cooled to room temperature (RT) and diluted with diethyl
ether (500 mL). The reaction is quenched with a mixture of CELITE® and
Na2SO4.10 H20 (1:1) is added portionwise over 15 min. The mixture is filtered and
concentrated under a vacuum to afford the title compound as a colorless oil (17.54 g,
90%). LC-ES/MS m/z 284 (M+l).
Preparation 3
(2S)-N-Benzyl-4-methoxy-N-[(lS)-l-phenylethyl]butan-2-amine
(3S)-3-[Benzyl-[(lS)-l-phenylethyl]amino]butan-l-ol (17.54 g, 61.9 mmol) is
dissolved in anhydrous THF (186 mL) and cooled to 0 °C under an argon atmosphere.
Sodium hydride (4.95 g, 60% suspension in mineral oil, 123.8 mmol) is added
portionwise over 10 min. The mixture is stirred at 0 °C for 15 min, and then allowed
to warm to RT. Methyl iodide (10.54 g, 74.28 mmol) is added dropwise over 30 min.
After stirring for 30 additional min, the reaction is quenched by the addition of a
saturated solution of NH4C 1 in water. The layers are separated and the aqueous layer
is extracted with diethyl ether (2 100 mL). The combined organic layers are dried
over MgS0 4, concentrated, and the crude is purified by normal phase chromatography
(two 120 g silica-gel cartridges, 10% of methyl -butyl ether in hexanes) to afford
the title compound as a colorless oil (14.96 g, 81%). LC-ES/MS m/z 298 (M+l).
Preparation 4
(S)-4-methoxybutan-2-amine hydrochloride
(2S)-N-Benzyl-4-methoxy-N-[(lS)-l-phenylethyl]butan-2-amine (14.96 g,
50.29 mmol) is dissolved in methanol (400 mL). The solution is deoxygenated by
bubbling nitrogen through it. 20% Palladium hydroxide on carbon (1.50 g) is added
to the solution and the resulting suspension is saturated with hydrogen and stirred
under a hydrogen atmosphere for 16 h. The main product present at this time is the
mono de-benzylated product. The suspension is filtered through a pad of CELITE®,
and 1.1 g of 20% palladium hydroxide on carbon is added to the resulting solution.
The suspension is stirred for 24 h under a hydrogen atmosphere. The suspension is
filtered through a pad of CELITE®, and a 2 N solution of HC1 in diethyl ether (60
mL) is added to the mixture and stirred for 30 min. The solution is concentrated
under reduced pressure to afford the title compound as a white solid (7.01 g, 99%). ¾
NMR(400 MHz, CDC13); 1.48 (3H, d, J = 6.8 Hz), 1.8-1.9 (1H, m), 2.0-2.1 (1H,
m), 3.37 (3H, s), 3.5-3.7 (3H, m), 8.3 (3H, br).
Preparation 5
(R)-N-[( 1S)-3-Methoxy- 1-methyl-propyl]-2-methyl-propane-2-sulfinamide
The following procedure is adapted from Ellman, J . A. et al J. Org. Chem.
2007, 72, 626-629.
To a 1N solution of HC1 (7.0 mL, 7.00 mmol) is added 1,3,3-
trimethoxybutane (53.19 mL, 337.38 mmol) dropwise, and the resulting solution is
heated to 50 °C and stirred for 30 min. Sodium bicarbonate (16.50 g, 196.41 mmol) is
added to the mixture, previously cooled to RT, followed by diethyl ether and MgSC^.
Filtration followed by evaporation of the solvent affords the keto-ether intermediate,
4-methoxybutan-2-one as a yellow oil. The oil is added to a solution of (R)-(+)-2-
methyl-2-propanesulfinamide (36.80 g, 303.64 mmol) and titanium (IV) ethoxide
(123.14 g, 539.80 mmol) in THF (482 niL) at 25 °C under a nitrogen atmosphere.
The resulting yellow suspension is heated to 60 °C and stirred at that temperature for
16 h. The reaction mixture is cooled to RT and then to -48 °C. 1.0 M Lithium tri(secbutyl)
borohydride in THF (539.80 mL, 539.80 mmol) is added dropwise. The
reaction mixture is allowed to warm to RT. After 1 h, the reaction mixture is cooled
to 0 °C and methanol ( 1100 mL) is added while being rapidly stirred until gas
evolution is no longer observed. The resulting suspension is filtered through a plug of
CELITE®, and the filter cake is washed with ethyl acetate. The filtrate is washed
with brine, and the brine layer is extracted twice with ethyl acetate. The combined
organic layers are dried over a2S0 4, filtered and evaporated to a yellow oil.
The crude is adsorbed onto silica gel and purified through a silica gel column
using a hexane/ethyl acetate gradient (from 7:1 to 100% ethyl acetate) to afford the
desired product. Other fractions, containing an apolar impurity and the desired
product are collected and purified again by silica gel chromatography. The apolar
impurity is removed with hexane/ethyl acetate, 4:1. The desired product is eluted
with dichloromethane/methanol, 95:5 to obtain additional material. The two batches
of material are combined to give 38 g (54%) which is a ratio of about 3:1 of the
desired/undesired diastereomer as seen by LCMS.
The material (38 g) is combined with another lot of material (23 g) that is
made using the same general procedure and the diastereomers (3:1 ratio, 6 1 g) are
separated by chiral phase high performance liquid chromatography (Stationary phase:
OD-H; Column Size: (20 , 80 x 250 mm); Elution mode: isocratic; Mobile phase:
hexane/isopropanol; Flow rate: 300 mL/min; UV detection: 215.16 nm; Loading: 4
g/6 min. The first eluting peak is the minor diastereomer, TR = 4.75 min. The second
eluting peak is the major diastereomer (titled compound), TR = 6.61 min. The title
compound is obtained as a slight yellow oil (43.5 g) from the chiral chromatography.
ES/MS m/z 208 (M+l); > 98% ee.
Preparation 6
(S)-4-methoxybutan-2-amine hydrochloride
Hydrogen chloride, 4.0 M in dioxane (110.15 g, 419.61 mmol) is added to a
solution of (R)-N-[(lS)-3-methoxy-l-methyl-propyl]-2-methyl-propane-2-sulfinamide
(43.5 g, 209.80 mmol) in 1,4-dioxane (109 mL) at 0 °C and the reaction mixture is
stirred for 1 h at RT. The solvent is concentrated under reduced pressure, the residue
is re-suspended in toluene and the solvent is evaporated under reduced pressure. The
residue is dried under vacuum for 15 min. THF is added and a white solid
precipitates. The white solid is filtered off, washed with THF, allowed to dry and
collected to afford the title compound (25.4 g, 87%).
The absolute configuration of the amine can be confirmed by derivatization
with (S)-(-)-a-methoxy-a-trifluoromethylphenyl-acetic acid and comparison of the
NMR with the same derivative of the (S)-4-methoxybutan-2-amine of Preparation 4
obtained from the chiral route.
Preparation 7
(3S)-3 -Isothiocyanato- 1-methoxy -butane
(S)-4-Methoxybutan-2-amine hydrochloride (25.4 g, 181.92 mmol) is
suspended in THF (609 mL) and triethylamine (TEA, 32.17 mL, 230.78 mmol) is
added. 1,1'-Thiocarbonyldiimidazole (46.74 g, 25 1.76 mmol) is added to the white
suspension (slightly exothermic reaction) and the resulting yellow suspension is
stirred under a nitrogen atmosphere overnight. Ethyl acetate (500 mL) is added to the
yellow suspension, followed by 1N HC1 (500 mL). The organic phase is separated
and washed with 1N HC1 (3 200 mL), water (200 mL), and brine (200 mL), dried
over Na2S0 4, filtered and concentrated under reduced pressure to afford the title
compound (25.3 g, 83%) as a yellow oil. ¾ NMR(400 MHz, CDC13); 1.37 (3H, d,
J= 6.6 Hz), 1.83 (2H, q, J= 6.6 Hz), 3.35 (3H, s), 3.6-3.4 (2H, m), 3.99 (1H, six, J=
6.6 Hz).
Preparation 8
Methyl 2,2-dimethyl-3-oxo-propanoate
Methyl 3-hydroxy-2,2-dimethyl-propanoate (52.4 g, 396.49 mmol) is
dissolved in dichloromethane (495 mL) and the mixture is cooled in an ice-water bath.
Trichloroisocyanuric acid (101.36 g, 436.14 mmol) is added portionwise, followed by
2,2,6,6-tetramethylpiperidine-N-oxide (6.20 g, 39.65 mmol). The mixture is stirred at
0 °C for 15 min and then allowed to warm to RT and stirred for an additional 60 min.
The solid is then filtered through CELITE® and rinsed with dichloromethane (300
mL). The filtrate is washed with a saturated solution of a2C0 in water. The
organic phase is dried over Na2S0 4, filtered, and concentrated under reduced
pressure to afford the title compound (41.24 g, 80%) as a greenish oil. The product is
used without further purification in the next reaction step. H NMR(400 MHz,
CDC13); 1.34 (6H, s), 1.34 (6H, s), 3.74 (3H, s), 9.64 (1H, s).
Preparation 9
6-Chloro-3-nitro-pyridin-2-ylamine (1254 g, 7.23 mol), triethylamine (1510
mL, 10.84 mol) and acetonitrile (10 L) are charged into a 20 L, 4-neck round bottom
flask equipped with a mechanical stirrer under nitrogen. To the resulting yellow
suspension, copper(I) iodide (13.9 g, 72.3 mmol) and
bis(triphenylphosphine)palladium (II) chloride (50.72 g, 72.3 mmol) are added. The
resulting pale orange suspension is cooled to 0-5 °C and then degassed during 10 min
with nitrogen. A solution of l-ethynyl-2,4-difluoro-benzene ( 1100 g, 7.95 mol)
dissolved in acetonitrile (2.5 L) is added dropwise during 60 min. The resulting
mixture is left stirring at RT (30 °C) overnight. The mixture is cooled to 0-5 °C.
Toluene (6 L) is added to the suspension and the mixture is stirred for 45 min and
filtered though a frit. The solid is washed with toluene (3 3 L), water (2 x 3 L) and
is dried overnight in a vacuum oven, to obtain the title compound as a yellow solid
(1750 g, 92%). LC-ES/MS m/z 276 (M+l).
Preparation 10
l-(6-Amino-5-nitro-2-pyridyl)-2-(2,4-difluorophenyl)ethane-
To a cold suspension (0-10 °C) of 6-[2-(2,4-difluorophenyl)ethynyl]-3-nitropyridin-
2 -amine (500 g, 1.82 mol) in acetone (10 L), is added cold buffer [NaH2P0 4
(0.8 M) /Na2HP0 4 (0.8 M) = 85/15 (V/V)] (pH = 6.0; 0-10 °C; 10 L). The
temperature is maintained at 15 °C. Potassium permanganate (1035 g, 6.55 mol) is
added portionwise (3 portions). The mixture is stirred for 4 h at 15 °C. The pH is
adjusted to pH = 5.0 and the temperature is kept below 15 °C. A 28% sodium
thiosulfate solution (2054 mL, 3.64 mol) is added slowly, maintaining the temperature
below 15 °C and the pH below 7.5. Brine (7.5 L) and a mixture of methyl -butyl
ether (3.75 L) and ethyl acetate (3.75 L) are added to the suspension. The mixture is
stirred for 15 min at 13 °C. The two phases are separated and the aqueous brown
suspension is extracted twice with methyl -butyl ether (3.5 L). The combined
organic layers are collected and washed with brine (2 x 3 L), dried over Na2S0 4,
filtered, and the solvent is evaporated under reduced pressure to obtain the title
compound as a yellow solid (375 g). The experiment is repeated under the same
conditions twice more. The resulting batches are combined to afford 1080 g. LCES/
MS m/z 308 (M+l).
Preparation 11
Methyl 2-[4-(6-amino-5-nitro-2-pyridyl)-5-(2,4-difluorophenyl)-lH-imidazol-2-yl]-2-
methyl-propanoate
To a round bottom flask with a reflux condenser are added l-(6-amino-5-nitro-
2-pyridyl)-2-(2,4-difluorophenyl)ethane-l,2-dione (50 g, 162.75 mmol), ammonium
acetate (126.72 g, 1.63 mol), methyl 2,2-dimethyl-3-oxo-propanoate (42.36 g, 325.51
mmol) and 1,4 dioxane (163 mL). The reaction mixture is heated to 80 °C during 1.5
h. The initial orange solution becomes dark with heating. The reaction mixture is
concentrated under reduced pressure to eliminate the dioxane and the residue is dried
under a high vacuum overnight. The residue is re-dissolved in ethyl acetate (800 mL)
and extracted with a 2 M solution of a2C0 in water. The organic phase is dried
over MgS0 4, concentrated, and dried under a high vacuum overnight to afford the
title compound as a crude orange solid (80 g) that is used in the next step without
further purification. LC-ES/MS m/z 418 (M+l).
Preparation 12
Methyl 2-[5-(2,4-difluorophenyl)-4-(6-hydroxy-5 -nitro-2-pyridyl)- 1H-imidazol-2-yl] -
2-methyl-propanoate
To a solution of methyl 2-[4-(6-amino-5-nitro-2-pyridyl)-5-(2,4-
difluorophenyl)-lH-imidazol-2-yl]-2-methyl-propanoate (56 g, 134.17 mmol) in
dimethyl sulfoxide (DMSO, 400 mL) and water (320 mL), is added sulfuric acid 95-
97% (80 niL) dropwise. Then the mixture is cooled to 0 °C. To the above mixture a
solution of sodium nitrite (18.70 g, 268.35 mmol) in water (80 mL) is added dropwise
over 15 min at 0 °C. The reaction mixture is stirred for 20 min at that temperature
and then the cooling bath is removed and the temperature is allowed to rise to RT. To
the reaction mixture is added a 0.8 M aqueous solution of buffered sodium phosphate
monobasic (1200 mL, pH = 6). A yellow suspension appears. This suspension is
stirred at RT for 1 h. The solid is filtered, washed with water, and dried in the oven to
afford the title compound as an orange solid (49.5 g, 88%). LC-ES/MS m/z 419
(M+l).
Preparation 13
Methyl 2-[4-(5-amino-6-hydroxy-2-pyridyl)-5-(2,4-difluorophenyl)-lH-imidazol-2-
-2-methyl-propanoate
A mixture of methyl 2-[5-(2,4-difluorophenyl)-4-(6-hydroxy-5-nitro-2-
pyridyl)-lH-imidazol-2-yl]-2-methyl-propanoate (49.5 g, 118.32 mmol) and
palladium 5% weight (dry basis) on activated carbon (4.95 g, 2.33 mmol) in methanol
(1.18 L) is stirred under a hydrogen atmosphere (balloon) at RT overnight. The
suspension is filtered through CELITE®, rinsed with methanol, and the filtrate is
concentrated under reduced pressure to afford the crude title compound (39 g) as a
brown solid.
The crude material (90 g, 23 1.74 mmol), from multiple runs, is purified as
follows. The material is suspended in a 1:1 mixture of dichloromethane (450 mL) and
ethyl acetate (450 mL). The suspension is stirred at RT overnight. The suspension is
filtered off and the solid is washed with a 1:1 mixture of dichloromethane/ethyl
acetate. The brown solid is allowed to dry and collected to give 67 g of the title
compound with >98% purity by liquid chromatography mass spectrometry. LCES/
MS m/z 389 (M+l).
Preparation 14
Methyl 2-[5-(2,4-difluorophenyl)-4-[2-[[(lS)-3-methoxy-l-methylpropyl]
amino]oxazolo[5,4-b]pyridin-5-yl]-lH-imidazol-2-yl]-2-methyl-propanoate
(3S)-3-Isothiocyanato-l-methoxy-butane (24.68 g, 169.94 mmol) is added to a
suspension of methyl 2-[4-(5-amino-6-hydroxy-2-pyridyl)-5-(2,4-difluorophenyl)- 1Himidazol-
2-yl]-2-methyl-propanoate (55 g, 141.62 mmol) in ethanol (550 mL) at RT.
The reaction mixture is stirred under reflux overnight and then cooled to 50 °C.
Dicyclohexylcarbodiimide (37.99 g, 184.10 mmol) is added to the mixture and the
resulting suspension is stirred under reflux for 20 h. The reaction is allowed to reach
RT and the solvent evaporated under reduced pressure. The residue is absorbed in
silica gel and purified through a silica gel column (first using dichloromethane as an
eluent to remove the most apolar impurities and then with dichloromethane/methanol
95:5 to elute the desired product) to afford the title compound (52 g, 74%) as a dark
brown foam. LC-ES/MS m/z 500 (M+l).
Preparation 15
2-[( 1S)-2-Hydroxy- 1-methyl-ethyl] isoindoline- 1,3-dione
A mixture of (2S)-2-aminopropan-l-ol (26 mL, 333 mmol) and phthalic
anhydride (51.7 g, 349.4 mmol) is heated at 140 °C overnight. During this time the
solid becomes an orange liquid. The reaction is cooled to RT and diluted with ethyl
acetate (10 mL/g). The organic phase is washed with saturated aHC0 and 10%
citric acid, dried over MgSC , filtered, and concentrated to afford the title compound
(68.3 g, 98%) as a white solid that is used without further purification. LC-ES/MS
m/z 206 (M+l).
Preparation 16
2-[( 1S)-2-Ethoxy- 1-methyl-ethyl] isoindoline- 1,3-dione
To a solution of 2-[(lS)-2-hydroxy-l-methyl-ethyl]isoindoline-l,3-dione (47
g, 229 mmol) and iodoethane (89.3 g, 572.5 mmol) in THF (376 mL) is added
potassium tert-butoxide (64.25 g, 572.5 mmol) in one portion. The mixture is stirred
under a nitrogen atmosphere for 15 h . The mixture is diluted with ethyl acetate (200
mL) and washed with brine (200 mL). The aqueous phase is extracted with ethyl
acetate (2 x 100 mL). The combined organic extracts are dried over MgS0 4, filtered,
concentrated under reduced pressure, and then dried under high vacuum to afford the
title compound (39.4 g,74%) as an orange solid that is used without further
purification. LC-ES/MS m/z 234 (M+l).
Preparation 17
(2S)- 1-Ethox ropan-2-amine hydrochloride
2-[(lS)-2-Ethoxy-l-methyl-ethyl]isoindoline-l,3-dione (12.84 g, 55 mmol) is
dissolved in methanol (120 mL). Hydrazine monohydrate (6.9 mL, 138 mmol) is
added slowly and the mixture is stirred at 40 °C for 4 h (a white solid is formed).
NaOH ( 1 mL) is added and the pH rises to 13-14. The solid is filtered and washed
with dichloromethane. The filtrate layers are separated and the aqueous layer further
extracted with dichloromethane. The combined organic layers are dried over MgS0 4
and filtered. 2 N HC1 in ether (70 mL, 140 mmol) is added to the solution. The
mixture is stirred for 15 min and the solvent evaporated under reduced pressure to
give the title compound as a white solid (6.61 g, 86%). H NMR(400 MHz, CD3OD);
1.22 (t, 3 H, J = 7.02 Hz), 1.28 (d, 3 H, J = 6.52 Hz), 3.42 (m, 2H), 3.58 (m, 3H).
Preparation 18
(2S)-l-Ethoxy-2-isothiocyanato-propane
To a solution of (2S)-l-ethoxypropan-2-amine hydrochloride (2 g, 12.03
mmol) in dimethylformamide (DMF, 20 mL) and TEA (1.85 mL, 13.24 mmol) is
added , -thiocarbonyldiimidazole (2.36 g, 13.24 mmol). The mixture is stirred
under a nitrogen atmosphere for 16 h. The mixture is diluted with ethyl acetate and
washed thoroughly with 1N HC1, water, and brine, dried over MgS0 4, and
concentrated under reduced pressure (bath temperature not to exceed 20 °C to avoid
product evaporation) to obtain crude material (1.84 g) containing the title compound
that is used as is without further purification. H NMR(400 MHz, CDC13); 1.26 (t,
3H, J= 7.13 Hz), 1.33 (d, 2H, J = 6.63 Hz), 3.46 (dd, J = 5.86, 1.62 Hz, 2H), 3.55 (dd,
J = 13.98, 6.97 Hz, 2H), 3.93 (m, 1H).
Preparation 19
3-Methyloxetane-3 -carbaldehyde
(3-Methyloxetan-3-yl)methanol (6.0 g, 58.75 mmol) is dissolved in
dichloromethane ( 117 mL). Trichloroisocyanuric acid (13.93 g, 59.92 mmol) is
added portionwise at -5 °C followed by the addition of 2,2,6,6-tetramethylpiperidine1-
oxyl (TEMPO) (0.92 g, 5.87 mmol). The reaction mixture is stirred at -5 °C for 20
min, allowed to warm to RT, and stirred for 20 additional min. The mixture is filtered
through a pad of CELITE®, diluted with dichloromethane (200 mL), and washed with
saturated aqueous Na2C0 3 (100 mL), 1N HC1 (100 mL) and brine (50 mL). The
organic portion is concentrated to afford the title compound as an orange oil (4.17 g,
71%) that is used without further purification. H NMR(400 MHz, CDC13); 1.48 (s,
3H), 4.50 (d, 2H, J = 6.34 Hz), 4.88 (d, 2H, J = 6.34 Hz), 9.95 (s, 1H).
Alternate preparation:
Potassium bromide ( 11.65 g, 0.098 mol) is added to a mixture of (3-
methyloxetan-3-yl)methanol (200 g, 1.96 mol) and TEMPO (3.06 g, 0.019 mol) in
dichloromethane (2 L) at 0 °C. Then, an aqueous solution of 10% sodium
hypochlorite (1.6 L, 2.35 mol), adjusted to pH= 9 with solid aHC0 3 is added
dropwise to the above solution (3 h addition, internal temperature kept < 10 °C). The
resulting mixture is stirred for 15 min and the two phases are separated. The aqueous
phase is extracted with a 10% 2-propanol/dichloromethane mixture until no product is
detectable by thin layer chromatography in the aqueous phase. The combined organic
phases are washed with saturated sodium thiosulphate solution, dried over MgS0 4,
filtered, and concentrated to afford the title compound as an orange oil ( 114 g, 58%).
Preparation 20
1-Methoxycarbonylcyclopropanecarboxylic acid
Dimethyl cyclopropane- 1,1-dicarboxylate (26.08 mL, 189.87 mmol) is
dissolved in methanol (319 mL) and the solution is cooled to 0 °C. I NaOH (190
mL, 190 mmol, 1 eq) in water is added dropwise. The resulting mixture is stirred at
RT overnight. The solution is concentrated under reduced pressure to remove the
methanol and the resulting aqueous solution is washed with dichloromethane (3 x 50
mL) and acidified with 1N HC1 (pH = 2-3). The solution is then extracted with ethyl
acetate (5 x 100 mL) and dichloromethane (3 x 50 mL). The combined organic
portions are dried over MgS04, filtered, and concentrated to afford the title compound
(16.4 g, 60%). ¾ NMR(400 MHz, CDC13); 1.9-1.7 (m, 4H), 3.78 (s, 3H).
Preparation 21
Methyl 1-(hydroxymethyl)cyclopropanecarboxylate
1-Methoxycarbonylcyclopropane carboxylic acid (16.4 g, 113.89 mmol), TEA
(17.6 mL, 127.55 mmol), and THF (325 mL) are charged in a round bottom flask.
The mixture is cooled to -10 °C and isobutyl chloroformate (16.5 mL, 127.55 mmol)
is added dropwise. The solution is stirred for 1 h. In a separate flask, sodium
borohydride (13 g, 341.67 mmol) is dissolved in a mixture of THF (165 mL) and
water (40 mL) and cooled in an ice bath. The insoluble material is removed by
filtration from the first solution. To the borohydride solution is added the 1-
methoxycarbonylcyclopropane carboxylic acid solution described above, dropwise
over a period of 1.5 h. The resulting solution is stirred at the same temperature for 1
h. The reaction mixture is poured into a cooled 20% aqueous solution of citric acid
and extracted with ethyl acetate (3 x 150 mL). The combined organic layers are
washed with brine, dried over MgS0 4, filtered, and concentrated under reduced
pressure to afford the title compound (13.5 g, 91%). ¾ NMR(400 MHz, CDC13); 
0.9-0.8 (m, 2H), 1.3-1.2 (m, 2H), 3.62 (s, 2H) 3.69 (s, 3H).
Preparation 22
Methyl 1-formylcyclopropanecarboxylate
Methyl l-(hydroxymethyl)cyclopropanecarboxylate (16.0 g, 123.07 mmol) is
dissolved in dichloromethane (320 mL) and the mixture is cooled to -5 °C.
Trichloroisocyanuric acid (29.1 g, 125.5 mmol) is added portionwise followed by the
addition of TEMPO (1.9 g, 12.3 mmol). The reaction mixture is stirred at -5 °C for
20 min, allowed to warm to RT, and stirred for 20 min. The mixture is filtered
through a pad of CELITE® and diluted with dichloromethane (500 mL). The solution
is washed with saturated Na2C0 3 (300 mL), 1N HC1 (300 mL), brine (300 mL), and
saturated ammonium chloride (3 x 200 mL). The organic portion is dried over
MgS0 4, filtered, and concentrated under reduced pressure to obtain 19 g of the title
compound, still containing dichloromethane (theoretical 15.75 g). The material is
used as is in the next reaction. ¾ NMR(400 MHz, CDC13); 1.7-1.6 (m, 4H), 3.81
(s, 3H), 10.38 (s, 1H).
Preparation 23
6-[2-Cyclopropyl-5-(2,4-difluorophenyl)-lH-imidazol-4-yl]-3-nitro-pyridin-2-
A KIMAX® tube is charged with l-(6-amino-5-nitro-2-pyridyl)-2-(2,4-
difluorophenyl)ethane-l,2-dione (5 g, 16.28 mmol), 1,4-dioxane (50 mL), and
ammonium acetate (6.27 g, 81.38 mmol). Cyclopropanecarbaldehyde (3.42 mL,
48.83 mmol) is added dropwise to the mixture. The resulting mixture is purged with
nitrogen, the tube is sealed, and it is heated at 80 °C overnight; after which the
mixture is allowed to cool to RT. The mixture is then concentrated to dryness under
reduced pressure. Ethyl acetate (700 mL) and saturated NaHCC aqueous solution
are added. The organic layer is separated, washed with brine (3 x 250 mL), dried
over MgS0 4, and concentrated to afford the crude title compound (5.5 g) which is
used in the next step without further purification. LC-ES/MS m/z 358 (M+l).
Prepare the intermediates in the table below, by essentially following the procedure as
described in Preparation 23, using l-(6-amino-5-nitro-2-pyridyl)-2-(2,4-
difluorophenyl)ethane-l,2-dione and the appropriate aldehyde as starting materials.
*Reaction is run at 90 °C for 1.5 h. During workup a solid precipitates and is
collected from addition of bicarbonate solution. The filtrate is worked up as before to
obtain a red oil. The oil is sonicated in a 4:1 mixture of ethyl acetate/hexane to obtain
a suspension which is filtered.
Preparation 26
6-[2-Cyclopropyl-5-(2,4-difluorophenyl)-lH-imidazol-4-yl]-3-nitro-pyridin-2-ol
6-[2-Cyclopropyl-5-(2,4-difluorophenyl)-lH-imidazol-4-yl]-3-nitro-pyridin-2-
amine (5.51 g, 15.41 mmol) is suspended in dimethyl sulfoxide (DMSO, 32 mL),
water (25 mL), and concentrated H2S0 4 (6 mL). The suspension is cooled at 0 °C and
sodium nitrite (2.13 g, 30.8 1 mmol) is added portionwise at such a rate that the
temperature is maintained below 5 °C. The mixture is stirred at 0 °C for 30 min, and
then is allowed to warm to RT, and is stirred until liquid chromatography/mass
spectrometry (LC/MS) shows complete conversion of the starting material ( 1 hour).
A 0.8 M aqueous solution of sodium phosphate monobasic (200 mL) is added to the
mixture. A yellow suspension is formed. Aqueous 1N NaOH is then added until the
pH rises to 8. The mixture is stirred for 30 h, filtered, and the solid is rinsed with
water, and then dried under reduced pressure to afford the title compound (4.53 g,
82%). LC-ES/MS m/z 358.9 (M+1).
Prepare the intermediates in the table below, by essentially following the procedure as
described in Preparation 26, using the appropriate 3-nitro-pyridin-2-amine as starting
material.
Preparation 29
3-Amino-6-[2-cyclopropyl-5-(2,4-difluorophenyl)-lH-imidazol-4-yl]pyridin-2-ol
6-[2-Cyclopropyl-5-(2,4-difluorophenyl)-lH-imidazol-4-yl]-3-nitro-pyridin-2
ol (4.525 g, 12.63 mmol) is dissolved in ethanol (63 mL). The solution is degassed
with bubbling nitrogen gas. 10% Pd/C (920 mg) is added portionwise to the mixture
and the mixture is saturated with hydrogen. The mixture is stirred under a hydrogen
atmosphere (balloon) at RT over the weekend, at which time LC/MS shows complete
conversion. The suspension is filtered through a pad of CELITE® to remove the
catalyst and the solution is concentrated under reduced pressure to afford the title
compound (3.97 g, 89%). LC-ES/MS m/z 328.9 (M+1).
Prepare the intermediates in the table below, by essentially following the procedure as
described in Preparation 29, using the appropriate 3-nitro-pyridinol as starting
material.
Preparation 32
Methyl l-[5-(2,4-difluorophenyl)-4-[2-[[(lS)-2-ethoxy-l-methylamino]
oxazolo[5,4-b]pyridin-5-yl]-lH-imidazol-2-yl]cyclopropanecarboxylate
A mixture of methyl l-[4-(5-amino-6-hydroxy-2-pyridyl)-5-(2,4-
difluorophenyl)-lH-imidazol-2-yl]cyclopropanecarboxylate (4 g, 10.35 mmol) and
(2S)-l-ethoxy-2-isothiocyanato-propane (2.379 g, 15.53 mmol) are dissolved in
ethanol (34 mL). The mixture is heated to 85 °C in a sealed flask for 16 h.
Diisopropyl carbodiimide (3.21 g, 20.71 mmol) is added dropwise and the mixture is
stirred at 85 °C for 16 h, after which time an additional 3 g of diisopropyl
carbodiimide is added and the mixture is heated at 85 °C for an additional 4 h. The
solvent is evaporated and the residue is purified by normal phase chromatography
(120 g silica-gel cartridge, using a hexane-ethanol gradient to afford the title
compound (1.180 g, 24%). LC-ES/MS m/z 498.1 (M+l).
Preparations for synthesis of Example 1 Alternate
Preparation 33
(S)-N-[(lS)-3-Methoxy-l-methyl-propyl]-2-methyl-propane-2-sulfinamide
For a comparison of L-Selectride verses sodium borohydride in the reduction
of N-tert-butanesulfinyl imines see Faul, M. M. J. Org. Chem. 2007, 71, 6859-6862.
1,3,3-Trimethoxybutane (145.4 g, 0.98 mol) is combined with 1aqueous
hydrochloric acid (50.0 mL, 0.05 mol) and stirred for 1-2 h at RT under a nitrogen
atmosphere. THF (1.5 L) is added and the solvent is evaporated at standard
atmospheric pressure below 70 °C twice. THF (1.5 L) is added to prepare a solution
of 4-methoxybutan-2-one in THF. (S)-(-)-2-Methyl-2-propanesulfinamide (124.4 g,
1.03 mol) and titanium (IV) ethoxide (447.0 g, 1.96 mol) are added and the reaction
heated to 65-70 °C for 16-17 h. The reaction mixture is cooled to -10 to 0 °C.
Sodium borohydride (37.0 g, 0.98 mol) is added in portions, and then the mixture is
stirred for 1-2 h at the same temperature. The reaction mixture is warmed to RT and
stirred for 1-2 h. It is then cooled to 10-20 °C and methanol (100 mL) is added
dropwise over 1-2 h. 25% Aqueous sodium chloride (300 mL) is added and the
mixture is warmed to RT. Ethyl acetate (500 mL) is added. The mixture is stirred for
1-2 h at RT and then filtered. The filtercake is rinsed with additional ethyl acetate
(807 mL). The layers are separated and the organic phase is washed with 25%
aqueous sodium chloride (1.0 L). The aqueous phase is extracted with ethyl acetate
(500 mL). The organic portions are combined, and the solvent is distilled at
atmospheric pressure (no vacuum) below 75 °C to arrive at a solution of 300-500 mL
total volume. Ethyl acetate (600 mL) and sodium thiosulfate (150.0 g) are added and
the mixture is stirred for 1-2 h at 20-30 °C. The mixture is filtered and the filtrate is
concentrated. The diastereomers are separated by supercritical fluid chromatography
to afford the title compound as a yellow oil (205.0 g, 65%). Column: ChiralPak® AD
10 , 50 x 300 mm; Elution mode: Isocratic; Mobile phase: CCVethanol; Flow rate:
280 mL/min; UV detection: 215.16 nm; Loading: 300 mg/mL. The first eluting peak
is the minor diastereomer, T = 15.17 min. The second eluting peak is the major
diastereomer representing the title compound, TR= 17.1 1 min.
Preparation 34
(3S)-3 -Isothiocyanato- 1-methoxy -butane
Under a nitrogen atmosphere are combined methanol (185 mL), THF (1.76 L),
and N-S-[(lS)-3-methoxy-l-methyl-propyl]-2-methyl-propane-2-sulfinamide (220.0
g, 1.06 mol) and cooled to -10 to 0 °C. Hydrochloric acid (1.26 L, 5.3 mol, 4.2 N in
THF) is added dropwise and the temperature is maintained below 10 °C. The reaction
mixture is stirred for 3^1 h at 0-10 °C, and is concentrated under reduced pressure
below 45 °C to a solution volume of 400.0-600.0 mL. THF (880 mL) is added and
the reaction mixture is concentrated under reduced pressure below 45 °C to a solution
volume of 400-600 mL. The reaction mixture is cooled to 20-30 °C and stirred for
0.5-1 h. Seed crystals of (5)-4-methoxybutan-2-amine, hydrochloride are added (5.0
g, 35.8 mmol). (Seed crystals can be generated from the solids obtained from
Preparations 4 or 6, or can be obtained using other methods common to one skilled in
the art, such as recrystallization of a small aliquot.) Methyl tert-butyl ether (660 mL)
is also added and the mixture is stirred at 20-25 °C for 2- h. The mixture is cooled
to 0-5 °C and stirred for - A h. The solids are collected by filtration and the
filtercake is washed with methyl -butyl ether ( 110 mL). The solids are transferred
to a reaction vessel and methyl -butyl ether (660 mL) is added at RT. Sodium
thiosulfate (270.0 g, 1.9 mol) and sodium hydroxide (42.5 g, 1.06 mol) are added and
the mixture is stirred for 1-2 h at 10-20 °C. The mixture is filtered and the filtercake
is washed with methyl -butyl ether (440 mL) to provide (5)-4-methoxybutan-2-
amine as a crude solution in methyl -butyl ether (87.5 g). The material is used in
the next reaction as follows.
Under a nitrogen atmosphere N , N -thiocarbonyldiimidazole (97.0 g, 0.55 mol)
and THF (470 mL) are added and the mixture is stirred for 15-30 min. The mixture
is cooled to -10 to 0 °C, a solution of (5)-4-methoxybutan-2-amine (46.9 g, 0.455
mol) in methyl tert-butyl ether (389 mL) is added, and the reaction mixture is warmed
to 10-20 °C. The reaction mixture is stirred at this temperature for 15-20 h, and then
is cooled to 0-10 °C. Hydrochloric acid (275 mL, 4 N in water) is added to arrive at a
pH of 1 to 2. The reaction mixture is warmed to RT and the layers are separated.
The aqueous layer is extracted with ethyl acetate (235 mL) and the organic layers are
combined and washed with water (140 mL). The organic solution is concentrated
under reduced pressure below 45 °C, ethyl acetate (21 1.5 mL) is added, and the
solution is concentrated under reduced pressure below 45 °C twice, and ethyl acetate
(235 mL) is added. Sodium thiosulfate (32.3 g, 227.0 mmol) is added, the solution is
filtered, and the filtercake is washed with ethyl acetate (104 mL). The filtrate is
concentrated under reduced pressure below 45 °C to furnish the title compound as a
yellow oil (55.0 g, 77%).
Preparation 35
Methyl 2,2-dimethyl-3 -oxo-propanoate
Methyl 3-hydroxy-2,2-dimethyl-propanoate (25.4 kg, 192.2 mol) and
dichloromethane (24 1 L) are combined under a nitrogen atmosphere at RT with
stirring. (2,2,6,6-Tetramethyl-piperidin-l-yl)oxyl (0.61 kg, 3.9 mol) is added and the
reaction mixture is cooled to 0-5 °C. Trichloroisocyanuric acid (3 1.2 kg, 134.5 mol)
is added portionwise at 0-5 °C and the reaction mixture is stirred for 16-18 h at this
temperature. The reaction is filtered and the filtercake is washed with
dichloromethane (25.4 L) and the filtrate concentrated under reduced pressure below
50 °C. 1,4-Dioxane (25.4 L) is added and the organic phase is concentrated under
reduced pressure below 65 °C to obtain the title compound as a yellow liquid (127.8
kg, 77%) that is used without further purification.
Preparation 36
6-[2-(2,4-Difluorophenyl)ethynyl]-3-nitro-pyridin-2-amine
6-Chloro-3-nitro-pyridin-2-ylamine (16.2 kg, 93.3 mol), acetonitrile (130.8 L),
cuprous iodide (0.18 kg, 1.0 mol), and bis(triphenylphosphine) palladium (II) chloride
(0.66 kg, 0.9 mol) are combined under a nitrogen atmosphere at 20-25 °C with
stirring. Triethylamine (19.7 L, 141.3 mol) is added and the mixture is heated to 30-
35 °C. A solution of l-ethynyl-2,4-difluoro-benzene (18.0 kg , 130.3 mol) in
acetonitrile (32.6 L) is added under a nitrogen atmosphere at 30-35 °C. The mixture
is stirred at 15-25 °C for 2- h. Toluene (80.0 L) is added and the mixture is stirred
for 0.5-1 h, then cooled to 0-5 °C and stirred for 2-4 h. The reaction mixture is
centrifuged and the filter cake is rinsed with toluene (2 x 64 L) and water (2 x 32.4
L). The solids are dried under reduced pressure below 50 °C to furnish the title
compound as a yellow solid (21.7 kg, 83%).
Preparation 37
l-(6-Amino-5-nitro-2-pyridyl)-2-(2,4-difluorophenyl)ethane-l,2-dione
6-[2-(2,4-Difluorophenyl)ethynyl]-3-nitro-pyridin-2-amine (2.0 kg, 7.3 mol)
and acetone (40.5 L) are added to a reactor under a nitrogen atmosphere and the
mixture is cooled to 0-10 °C with stirring. A buffering solution of water (38.3 L),
sodium dihydrogen phosphate (3.3 kg), and disodium hydrogen phosphate (0.7 kg) is
added at 0-15 °C. The mixture is cooled to 3-6 °C and is charged with solid
potassium permanganate (4.1 kg, 25.9 mol) at 3-6 °C. The mixture is stirred for 3 h
to 5 h, and then portions of the reaction mixture are transferred to a vessel containing
water (9.3 L) and sodium thiosulfate pentahydrate (3.6 kg) at 15-20 °C. The mixture
is stirred at 15-25 °C. Water (50 L) is added and the mixture stirred for 0.5-1 h and
is filtered. The filtrate is concentrated under reduced pressure below 45 °C. When
the distillation of solvent is complete, water (40 L) is added at 20-25 °C and the
mixture is stirred for 0.5-1 h. The solids are collected by filtration and the filtercake
is dried below 40 °C to obtain the title compound as a yellow solid (1.7 kg, 75%).
Preparation 38
Methyl 2-[4-(6-amino-5-nitro-2-pyridyl)-5-(2,4-difluorophenyl)-lH-imidazol-2-yl]-2-
methyl-propanoate, methanesulfonate
Ammonium acetate (30.0 kg, 389.2 mol), 1,4-dioxane (193.6 L), and methyl
2,2-dimethyl-3-oxo-propanoate (10.2 kg, 78.4 mol) are combined under a nitrogen
atmosphere with stirring at 20-25 °C for 0.5-1 h. l-(6-Amino-5-nitro-2-pyridyl)-2-
(2,4-difluorophenyl)ethane-l,2-dione (18.5 kg, 60.2 mol) is added and the mixture is
stirred for 10-14 h at 20-25 °C. Toluene (36.9 L) is added and the solution
concentrated under reduced pressure below 65 °C. Toluene (76.8 L) is added and
then the solution is concentrated under reduced pressure below 65 °C. Toluene (36.9
L) and ethyl acetate (37. 1 L) are added and the mixture is filtered. The filtrate is set
aside and the filtercake is transferred into a separate reactor and ethyl acetate (37.1 L)
is added. The mixture is heated to 50-60 °C with stirring for 20-30 min. The
mixture is cooled to 20-25 °C, filtered and the filtrate is combined with the previous
filtrate. The combined filtrates are concentrated under reduced pressure below 60 °C
and toluene (76.8 L) is added. The mixture is concentrated under reduced pressure
below 65 °C. Ethyl acetate (18.6 L) and toluene (18.3 L) are added and the solution
heated to 50-70 °C. Methanesulfonic acid (4.3 L, 66.2 mol) in ethyl acetate (18.6 L)
is added and the reaction is stirred for 1-2 h. The reaction is cooled to 10-25 °C and
is stirred for 2-5 h. The solids are collected by filtration, and the filtercake is washed
with ethyl acetate (18.6 L) to provide the title compound as a brown solid (17.0 kg,
96.2% purity, 46.2% yield). H NMR ( -DMSO, 400 MHz) 1.69 (s, 6H), 2.36 (s,
3H), 3.68 (s, 3H), 6.89 (d, 1H, J = 8.8 Hz), 7.00 (s, 1 H), 7.25 (s, 1H), 7.12 (s, 1H),
7.27 (dd, 1H, J = 8.4 Hz, 1.6 Hz), 7.45 (ddd, 1H, J = 10.0 Hz, 10.0 Hz, 2.4 Hz), 7.83-
7.68 (m, 2 H), 8.40 (d, 1H, J = 8.8 Hz).
Preparation 39
Methyl 2-[5-(2,4-difluorophenyl)-4-(6-hydroxy-5-nitro-2-pyridyl)-lH-imidazol-2-yl]-
2-methyl-propanoate
Under a nitrogen atmosphere methyl 2-[4-(6-amino-5-nitro-2-pyridyl)-5-(2,4-
difluorophenyl)-lH-imidazol-2-yl]-2-methyl-propanoate methanesulfonate (68.9 g,
134.2 mmol), dimethyl sulfoxide (275.5 mL), THF ( 116.2 mL), and water (303.2 mL)
are added and the mixture is stirred at 20-25 °C. Sulfuric acid 95-97% (93.6 mL) is
added dropwise to the reaction mixture and the temperature is maintained below 30
°C. The reaction mixture is cooled to 0-5 °C, and a solution of sodium nitrite (18.6 g,
0.27 mmol) in water (82.7 mL) is added at 0-10 °C. The reaction mixture is stirred
for 1-2 h at this temperature. 10% Aqueous sodium dihydrogen phosphate (930.0
mL) is added dropwise to maintain the temperature below 25 °C. The resulting
mixture is stirred for 2-3 h at 15 25 °C, and the solids are collected by filtration. The
filtercake is washed with water (138 mL) and the solids are transferred into a reaction
vessel. Methanol (566 mL) is added and the mixture is heated to 60-65 °C for 1-2 h.
Water (87 mL) is added and the mixture is stirred at 60-65 °C for 1-2 h. The reaction
mixture is cooled to 15-25 °C and the mixture is stirred at 15-25 °C for 2- h. The
mixture is filtered, the cake is washed with methanol (87 mL), and is dried under a
vacuum below 70 °C to provide the title compound as a yellow solid (53.28 g, 93%).
Preparation 40
Methyl 2-[4-(5-amino-6-hydroxy-2-pyridyl)-5-(2,4-difluorophenyl)-lH-imidazol-2-
yl]-2-methyl-propanoate
Methyl 2-[5-(2,4-difluorophenyl)-4-(6-hydroxy-5-nitro-2-pyridyl)-lHimidazol-
2-yl]-2-methyl-propanoate (90.0 g, 0.22 mol), wet 10% Pd/C (4.5 g), and
methanol (1.77 L) are combined at 15-25 °C. The reaction is stirred under 20-25
psig hydrogen atmosphere for 3-6 h. The reaction mixture is filtered over
diatomaceous earth, and the filter aid is washed with methanol (227 mL). The filtrate
is concentrated under reduced pressure below 40 °C, and methyl tert-butyl ether
(729.3 mL) is added. The MTBE is removed under reduced pressure below 40 °C,
and more methyl tert-butyl ether (729.3 mL) is added. The MTBE is removed under
reduced pressure below 40 °C. Methyl tert-butyl ether (182 mL) and methanol (46
mL) are added and the mixture heated to 50-60 °C for 1-2 h. The mixture is cooled
to 10-15 °C, and stirred for 2- h. The solids are collected by filtration and the
filtercake washed with methyl -butyl ether (61 mL). The solids are dried under
vacuum below 50 °C to furnish the title compound as a yellow solid (75.0 g, 88%).
Preparation 41
Methyl 2-[5-(2,4-difluorophenyl)-4-[2-[[(lS)-3-methoxy-l-methylpropyl]
amino]oxazolo[5,4-b]pyridin-5-yl]-lH-imidazol-2-yl]-2-methyl-propanoate
Dimethyl sulfoxide (713 mL) is degassed with nitrogen at 25-30 °C for 0.5-1
h under a nitrogen atmosphere. Methyl 2-[4-(5-amino-6-hydroxy-2-pyridyl)-5-(2,4-
difluorophenyl)-lH-imidazol-2-yl]-2-methyl-propanoate (35.0 g, 90.0 mmol) and
(35)-3-isothiocyanato-l-methoxy-butane (19.58 g, 0.14 mol) are added and the
reaction heated to 63-68 °C. The reaction mixture is stirred for 18-24 h at this
temperature and then add l-ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride (19.3 g, 100.7 mmol) is added in portions. The reaction mixture is
stirred for 2-4 h at 60-65 °C. Additional l-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (1.9 g, 9.9 mmol) is added if the reaction does not reach
complete conversion. The reaction mixture is cooled to 20-30 °C and is filtered over
diatomaceous earth. Ethyl acetate (35 1 mL) and water (350 mL) are added to the
filtrate. The layers are separated and the aqueous phase extracted with ethyl acetate
(3 12 mL). The organic layers are combined and washed with water (2 210 mL),
and then heptane (626 mL) is added. The solution is stirred for 0.5-1 h and filtered
over silica gel, rinsing with a mixture of ethyl acetate (351 mL) and heptane (348
mL). The solution is concentrated under reduced pressure below 45 °C and ethyl
acetate (156 mL) is added. Activated carbon (3.5 g) is added and the mixture heated
to 60-70 °C with stirring for 0.5-1 h. The rmixture is cooled to 20-30 °C, filtered,
and the filtrate concentrated under reduced pressure below 45 °C. Toluene (242 mL)
is charged to the resulting residue and the material concentrated under reduced
pressure below 45 °C. Toluene (40 mL) is added and the mixture heated to 60-70 °C
with stirring for 0.5-1 h. The mixture is cooled to 25-30 °C, stirred for 2-4 h, and
then cooled to 0-5 °C. The mixture is stirred at 0-5 °C for 2-4 h and the solids are
collected by filtration. The filtercake is washed with toluene (40 mL) and is dried
under reduced pressure below 60 °C to give the title compound as an off-white solid
(33.0 g, 71%).
Example 1
2-[5-(2,4-Difluorophenyl)-4-[2-[ [(1S)-3-methoxy- 1-methylpropyl]
amino]oxazolo[5,4-b]pyridin-5-yl]-lH-imidazol-2-yl]-2-methyl-propan-l-ol
Methyl 2-[5-(2,4-difluorophenyl)-4-[2-[[(lS)-3-methoxy-l-methylpropyl]
amino] oxazolo [5,4-b]pyridin-5 -yl] -1H-imidazol-2-yl] -2-methyl-propanoate
(497 mg, 0.99 mmol) is dissolved in a mixture of diethyl ether (5 mL) and THF (2.5
mL). The mixture is cooled to 0 °C and lithium borohydride (45.6 mg, 1.99 mmol) is
added portionwise. The reaction mixture is then stirred at RT under a nitrogen
atmosphere for 2 h. 1M HCl is slowly added until pH=l and the mixture stirred for
15 min at RT. The mixture is basified with solid NaHC0 and the layers are
separated. The aqueous layer is extracted with dichloromethane and the combined
organic layers are dried over MgSC^, filtered, and concentrated under reduced
pressure. The crude material is purified by normal phase chromatography (40 g
silica-gel cartridge, 20% ethanol in hexanes). A brown solid (298 mg) is obtained,
which is further purified by reverse phase chromatography (XBRIDGE™ column (5
, 19 x 100 mm): gradient between 35 and 38% of acetonitrile in ammonium
carbonate solution in water (pH = 9). Flow 25 mL/min) to afford 193 mg (41%) of
the title compound. LC-ES/MS m/z 472 (M+l). [a] D
22 +33.79° (c = 0.72,
methanol).
Example 1 Alternate Purification
2-[5-(2,4-Difluorophenyl)-4-[2-[[(lS)-3-methoxy-l-methylpropyl]
amino]oxazolo[5,4-b]pyridin-5-yl]-lH-imidazol-2-yl]-2-methyl-propan-l-ol
Methyl 2-[5-(2,4-difluorophenyl)-4-[2-[[(lS)-3-methoxy-l-methylpropyl]
amino] oxazolo [5,4-b]pyridin-5 -yl]-l H-imidazol-2-yl] -2-methyl-propanoate
(50 g, 100.1 mmol) is dissolved in a mixture of diethyl ether ( 1 L) and THF (500 mL).
The mixture is cooled to 0 °C and lithium borohydride (4.36 g, 200.19 mmol) is
added. The reaction mixture is stirred at RT under a nitrogen atmosphere for 2 h. 1
M HC1 (600 mL) is slowly added (gas evolution) and the resulting mixture is stirred
for 1.5 h at RT. The layers are separated and the aqueous phase is extracted with
methyl tert-butyl ether. The aqueous layer is basified (pH= 8) by the addition of 2 M
NaOH (200 mL) and is extracted with dichloromethane (3 x 400 mL). The combined
organic layers are dried over a2S0 4, filtered, and concentrated under reduced
pressure to a brown foam. The crude is eluted through a silica gel column (eluent:
dichloromethane/3N H in methanol 95:5) to obtain the desired product as a violet
colored foam (35 g). The solid is suspended in a mixture of 2:1 heptane/methyl tertbutyl
ether and sonicated. The suspension is stirred at RT overnight. The solid is
filtered and dried under a vacuum to afford the title compound as a crystalline offwhite
solid (30 g, 64%). MS (m/z): 472 (M+l).
Example 1: Alternate Route of Preparations 33-41
2-[5-(2,4-Difluorophenyl)-4-[2-[ [(1S)-3-methoxy- 1-methylpropyl]
amino]oxazolo[5,4-b]pyridin-5-yl]-lH-imidazol-2-yl]-2-methyl-propan-l-ol
2-Methyltetrahydrofuran (135 mL) is cooled to -5 to 0 °C under nitrogen and
lithium borohydride (4.95 g, 0.23 mol) is added in portions, maintaining the
temperature below 10 °C. A solution of methyl2-[5-(2,4-difluorophenyl)-4-[2-[[(lS)-
3-methoxy-l-methyl-propyl]amino]oxazolo[5,4-b]pyridin-5-yl]-lH-imidazol-2-yl]-2-
methyl-propanoate (45.0 g, 0.09 mol) in 2-methyltetrahydrofuran (225 niL) is added
drop-wise at -5 to 0 °C and stirred for 12-14 h. 2 M Aqueous hydrochloric acid (203
rnL) is added dropwise at -5 to 0 °C and the reaction mixture is heated to 30-40 °C
with stirring for 1-2 h. The reaction mixture is cooled to 15-25 °C and the layers are
separated. The organic phase is extracted with a mixture of water (135 mL) and 2 M
aqueous hydrochloric acid (45 mL), and the organic phase is discarded. The aqueous
layers are combined and 25% aqueous sodium hydroxide (75 mL) is added dropwise
to adjust to pH = 8-9. The aqueous is extracted with dichloromethane (225 mL) at RT
and the layers separated. The organic portion is washed with water (2 x 180 mL) and
then concentrated under reduced pressure below 40 °C. Methyl tert-butyl ether (23 1
mL) is added and the solution is concentrated under reduced pressure below 40 °C,
twice. Ethyl acetate (101 mL) is added and the mixture is heated to 50-60 °C with
stirring for 1-2 h. The solution is cooled to 0-5 °C with stirring for 2-4 h. The solids
are filtered and the filtercake is washed with heptane (66 mL). The solids are
transferred to a reaction vessel, ethyl acetate (181 mL) is added and then the mixture
is heated to 70-75 °C with stirring for 0.5-1 h. The mixture is cooled to 50-60 °C
and heptane (157 mL) is added dropwise and stirred for 2-4 h. The mixture is then
cooled to 10-15 °C with stirring for 2- h. The solids are filtered and the filtercake is
washed with heptane (66 mL). The solids are transferred to a reaction vessel and
ethyl acetate (406 mL) is added. The mixture is heated to 60-75 °C with stirring for
0.5-1 h. It is then cooled to 40^15 °C and is concentrate under reduced pressure
below 45 °C to arrive at a solution of approximately 200 mL total volume. The
mixture is heated to 70-75 °C with stirring for 0.5-1 h, and then cooled back down to
50 -60 °C. Heptane (268 mL) is added followed by seed crystals (2.25 g). (Seed
crystals can be generated from the solids obtained from previous lots of the product of
Example 1, or can be obtained using other methods common to one skilled in the art,
such as recrystallization of a small aliquot.) The mixture stirred at 50-60 °C for 2-4
h. The mixture is cooled to 10-15 °C and stirred for 2-4 h. The solids are collected
by filtration and the filtercake is washed with a mixture of ethyl acetate (18 mL) and
heptanes (16 mL). The cake is dried under reduced pressure below 65 °C to obtain
the title compound as an off-white solid (27.5 g, 63%). HPLC Method: Column:
ChiralPak® AD-H, 5 , 4.6 x 250 mm; Elution mode: Isocratic; Mobile phase:
Hexane/isopropanol/diethylamine (92:8:0.1); Flow rate: 1.0 mL/min; UV detection:
337 nm. TR = 22.6 min, 100% ee.
The Compound of Example 1, X-Ray Powder Diffraction (XRPD)
The XRPD patterns of crystalline solids are obtained on a Bruker D4
Endeavor X-ray powder diffractometer, equipped with a CuKa source = 1.54060 A)
and a Vantec detector, operating at 35 kV and 50 mA. The sample is scanned
between 4 and 40° in 2, with a step size of 0.009° in 2and a scan rate of 0.5
seconds/step, and with 0.6 mm divergence, 5.28 fixed anti-scatter, and 9.5 mm
detector slits. The dry powder is packed on a quartz sample holder and a smooth
surface is obtained using a glass slide. The crystal form diffraction patterns are
collected at ambient temperature and relative humidity. In the present case, a peak
position variability of ± 0.2 in 2will take into account these potential variations
without hindering the unequivocal identification of the indicated crystal form.
Confirmation of a crystal form may be made based on any unique combination of
distinguishing peaks (in units of ° 2), typically the more prominent peaks. The
crystal form diffraction pattern, collected at ambient temperature and relative
humidity, is adjusted based on NIST 675 standard peaks at 8.853 and 26.774 degrees
2-theta.
Table 1: X-ray powder diffraction peaks of Example 1 Form I
Peak Positions
Angle (°2-Theta) +/- Relative Intensity (% of d value
Peak
0.2° most intense peak) (angstroms)
1 15.06 100 5.88
2 19.94 85.5 4.45
3 10.31 60.8 8.57
4 20.78 60.4 4.27
5 17.91 59.9 4.95
6 19.25 40.1 4.61
7 16.16 39.3 5.48
8 9.33 35.7 9.47
9 21.86 31.5 4.06
10 26.61 27.7 3.35
T lus, crystalline 2-[5-(2,4-c ifluorophenyl)-4-[2-[[(l S)-3-methoxy- 1-methylpropyl]
amino] oxazolo [5,4-b]pyridin-5-yl] -1H-imidazol-2-yl] -2-methyl-propan- 1-ol
Form I of the present invention may be characterized by an X-ray diffraction pattern
using CuK radiation as having diffraction peaks (2-theta values) as described in
Table 1, and in particular having peaks at 15.06 in combination with one or more of
the peaks at 19.94, 10.3 1, and 20.78; and more particularly having a peak at 15.06;
with a tolerance for the diffraction angles of 0.2 degrees.
Example 1 (Free Base Form II):
The free base Form II of Example 1 is prepared by mixing 8.01 g of free base
in a 125 mL flask with 100 mL of methyl -butyl ether to give a brown slurry of
solid. The sample is slurried overnight at 300 rpm and 50 °C. After 18 hours, the
sample is a slurry of off-white solid under a wine-red supernatant. The sample is
evaporated to reduce the volume by approximately half, and the off-white solid is
recovered by vacuum filtration. The resulting cake of off-white solid is dried for 2
hours in a 65 °C vacuum oven. 7.15 g of solid is recovered (89%).
Table 2 : X-ray powder diffraction peaks of Example 1 Form II
Peak Positions
Peak Angle (°2-Theta) +/- 0.2° Relative Intensity (% of most intense d value
peak) (angstroms)
1 13.73 100 6.45
2 16.54 67.6 5.35
3 22.87 66.5 3.89
4 18.57 62.2 4.77
5 20.80 37.4 4.27
6 17.47 37.2 5.07
7 15.30 34.3 5.79
8 12.36 31.2 7.16
9 12.87 29.4 6.87
10 9.61 22.3 9.20
Thus, crystalline 2-[5-(2,4-difluorophenyl)-4-[2-[[(lS)-3-methoxy-l-methylpropyl]
amino]oxazolo [5,4-b]pyridin-5 -yl] -1H-imidazol-2-yl] -2-methyl-propan- 1-ol
Form II of the present invention may be characterized by an X-ray diffraction pattern
using CuK radiation as having diffraction peaks (2-theta values) as described in
Table 1, and in particular having peaks at 13.73 in combination with one or more of
the peaks at 16.54, 22.87, and 18.57; and more particularly having a peak at 13.73;
with a tolerance for the diffraction angles of 0.2 degrees.
Example 2
2-[5-(2,4-Difluorophenyl)-4-[2-[ [(1S)-3-methoxy- 1-methylpropyl]
amino]oxazolo [5,4-b]pyridin-5-yl] -1H-imidazol-2-yl]-2-methyl-propan- 1-ol,
methanesulfonate
2-[5-(2,4-Difluorophenyl)-4-[2-[[(lS)-3-methoxy-l-methylpropyl]
amino]oxazolo [5,4-b]pyridin-5-yl] -1H-imidazol-2-yl] -2-methyl-propan- 1-ol
(37.5 mg, 0.080 mmol) is dissolved in a 1:1 mixture of dichloromethane/methanol ( 1
mL total). A 0.5 M solution of methanesulphonic acid in methanol (0.16 mL) is
added dropwise. The mixture is stirred at RT for 30 min. The solvent is evaporated
under reduced pressure and the resulting residue is triturated twice with tert-butyl
methyl ether. The residue is dried under vacuum to afford the title compound (42 mg,
93%). LC- ES/MS m/z 472 (M+l).
Example 3
2-[5-(2,4-Difluorophenyl)-4-[2-[ [(1S)-3-methoxy- 1-methylpropyl]
amino]oxazolo[5,4-b]pyridin-5-yl]-lH-imidazol-2-yl]-2-methyl-propan-l-ol,
hydrochloride
To a slightly pink suspension of 2-[5-(2,4-difluorophenyl)-4-[2-[[(lS)-3-
methoxy-l-methyl-propyl]amino]oxazolo[5,4-b]pyridin-5-yl]-lH-imidazol-2-yl]-2-
methyl-propan-l-ol (25.7 g, 54.51 mmol) in methyl tert-butyl ether (771 mL) at 60
°C, is added a 4.0 M HCl solution in dioxane (16.35 mL , 65.41 mmol). The resulting
suspension is heated to 60 °C for 30 min and then allowed to reach RT gradually. A
solid is formed and is filtered under an inert atmosphere of nitrogen and quickly
collected and dried under vacuum at 60 °C overnight to provide the title compound as
a creamy solid (27 g, 98%). LC-ES/MS m/z 472 (M+l).
Example 4
2-[5-(2,4-Difluorophenyl)-4-[2-[[(lR)-3-methoxy-l-methylamino]
oxazolo[5,4-b]pyridin-5-yl]-lH-imidazol-2-yl]-2-methyl-propan-l-ol
The title compound is prepared essentially using the same synthetic route as
for its S enantiomer, with the difference that, in Preparation 1, (lR)-N-benzyl-lphenyl-
ethanamine is used instead of the S enantiomer. [CX]D22 -32. 11°, (c = 0.54,
methanol).
Example 5
2-[5-(2,4-Difluorophenyl)-4-[2-[[(lR)-3-methoxy-l-methylpropyl]
amino]oxazolo[5,4-b]pyridin-5-yl]-lH-imidazol-2-yl]-2-methyl-propan-l-ol
methanesulfonate
The title compound is prepared using essentially the same procedure as
described in Example 2 for its S enantiomer.
Example 6
5-[2-Cyclopropyl-5-(2,4-difluorophenyl)-lH-imidazol-4-yl]-N-[(lS)-3-methoxy-lmethyl-
propyl]oxazolo[5,4-b]pyridin-2-amine
A KIMAX® tube is charged with 3-amino-6-[2-cyclopropyl-5-(2,4-
difluorophenyl)-lH-imidazol-4-yl]pyridin-2-ol (0.7 g, 2.13 mmol) and ethanol (7
mL). (3S)-3-isothiocyanato-l-methoxy -butane (0.46 g, 3.2 mmol) is added, the flask
sealed, and the mixture is heated to 85 °C. After 16 h, N,N'-dicyclohexylcarbodiimide
(0.88 g, 4.26 mmol) is added and the mixture is stirred for 4 h at 85 °C in the
sealed tube. After this time, additional N,N'-dicyclohexylcarbodiimide (0.44 g, 2. 13
mmol) is added to the mixture. Heating is continued at 85 °C overnight. After this
time, additional N,N'-dicyclohexyl-carbodiimide (0.88 g, 4.26 mmol) is added to the
mixture, and heating is continued at 85 °C for 4 h. The crude reaction is concentrated
under reduced pressure, and the residue is purified by normal phase chromatography
(120 g silica-gel cartridge, dichloromethane - ethanol gradient). The fractions
containing the desired compound are further purified by semi-preparative reverse
phase high performance (LC/MS) using an XBRIDGE™ column (5 , 19 x 100
mm) and an isocratic program of 36% of acetonitrile in NH4HCO3 20 mM (pH 9), in
5 min at flow 25 mL/min to afford the title compound (0.15 g, 16%). LCES/MS m/z
440 (M+l); [a] D
22 +58.60°, (c = 0.50, methanol).
Example 7
5-[2-Cyclopropyl-5-(2,4-difluorophenyl)-lH-imidazol-4-yl]-N-[(lS)-3-methoxy-lmethyl-
propyl]oxazolo[5,4-b]pyridin-2-amine methanesulfonate
5-[2-Cyclopropyl-5-(2,4-difluorophenyl)- 1H-imidazol-4-yl] -N-[( 1S)-3 -
methoxy-l-methyl-propyl]oxazolo[5,4-b]pyridin-2-amine (0.090 g, 0.23 mmol) is
dissolved in a 1:1 mixture of dichloromethane and methanol (3 mL total). A 0.5 M
solution of methanesulfonic acid in methanol (0.47 mL) is added dropwise to the
solution. The mixture is stirred at RT for 30 min and then the solvent is evaporated
under reduced pressure. The residue is mixed with methanol and concentrated twice
to afford the title compound (0. 111 g, 89%). LC-ES/MS m/z 440 (M+l).
Example 8
5-[5-(2,4-Difluorophenyl)-2-(3-methyloxetan-3-yl)-lH-imidazol-4-yl]-N-[(lS)-3-
methoxy-l-methyl-propyl]oxazolo[5,4-b]pyridin-2-amine
A KIMAX® tube is charged with 3-amino-6-[5-(2,4-difluorophenyl)-2-(3-
methyloxetan-3-yl)-lH-imidazol-4-yl]pyridin-2-ol (2.28 g, 6.36 mmol) and ethanol
(18 mL). (3 S)-3-Isothiocyanato-l-methoxy -butane (1.39 g, 9.54 mmol) is added, the
flask sealed, and the mixture is heated to 85 °C. After 16 h, (3S)-3-isothiocyanato-lmethoxy-
butane (700 mg) is added and the mixture is stirred for 48 h at 85 °C in the
sealed tube. N,N'-diisopropylcarbodiimide (1.04 g) is added and the mixture is stirred
3 h at 85 °C in the sealed tube. The crude reaction mixture is concentrated under
reduced pressure and the residue purified by normal phase chromatography (120 g
silica-gel cartridge, hexane - ethanol). The desired compound elutes at 3% of ethanol
to give the title compound as a brown solid (2.61 g, 87%). LC-ES/MS m/z 470
(M+l); [a] D
22 +42.2°, (c = 0.50, methanol).
Example 9
5-[5-(2,4-Difluorophenyl)-2-(3-methyloxetan-3-yl)-lH-imidazol-4-yl]-N-[(lS)-3-
methoxy- 1-methyl-propyl] oxazolo [5,4-b]pyridin-2-amine methanesulfonate
5-[5-(2,4-Difluorophenyl)-2-(3-methyloxetan-3-yl)-lH-imidazol-4-yl]-N-
[(lS)-3-methoxy-l-methyl-propyl]oxazolo[5,4-b]pyridin-2-amine (0.72 g, 1.54 mmol)
is dissolved in a 1:1 mixture of dichloromethane/methanol (15 mL total). A 0.5 M
solution of methanesulfonic acid in methanol (3.07 mL) is added dropwise to the
solution. The mixture is stirred at RT for 30 min and then the solvent is evaporated
under reduced pressure. The residue is triturated with tert-butyl methyl ether to afford
the title compound as a brown solid (0.841 g, 97%). LC-ES/MS m/z 470 (M+l).
Example 10
[l-[5-(2,4-Difluorophenyl)-4-[2-[[(lS)-2-ethoxy-l-methyl-ethyl]amino]oxazolo[5,4-
b]pyridin-5-yl]-lH-imidazol-2-yl]cyclopropyl]methanol
Methyl l-[5-(2,4-difluorophenyl)-4-[2-[[(lS)-2-ethoxy-l-methylethyl]
amino]oxazolo[5,4-b]pyridin-5-yl]-lH-imidazol-2-yl]cyclopropanecarboxylate
(0.9 g, 1.99 mmol) is dissolved in dry diethyl ether (20 mL) and dry THF (7 mL)
under a nitrogen atmosphere and cooled to 0 °C. Lithium borohydride (87 mg, 3.99
mmol) is added portionwise and the mixture stirred at 0 °C for 1h. The remaining
reactants are quenched by adding 1N HC1 until pH=l to the mixture at RT dropwise
for 30 min. The mixture is washed with ethyl acetate, the aqueous layer basified
(until pH = 8) with NaOH, and extracted with dichloromethane. The combined
organic layers are dried over MgS0 4, filtered, and concentrated under reduced
pressure. The residue is purified by normal phase chromatography (120 g silica-gel
cartridge) using a gradient of hexane-ethanol to afford the title compound (0.56 g,
60%). LC-ES/MS m/z 470.2 (M+l); [a] D
22 -18.00°, (c = 0.50, MeOH); [a] D
22 -18.0°,
(c = 0.50, CHC13) .
Example 11
[l-[5-(2,4-Difluorophenyl)-4-[2-[[(lS)-2-ethoxy-l-methyl-ethyl]amino]oxazolo[5,4-
b]pyridin-5-yl]-lH-imidazol-2-yl]cyclopropyl]methanol methanesulfonate
[1-[5-(2,4-Difluorophenyl)-4-[2- [[( 1S)-2-ethoxy- 1-methylethyl]
amino]oxazolo[5,4-b]pyridin-5-yl]-lH-imidazol-2-yl]cyclopropyl]methanol
(0.56 g, 1.19 mmol) is dissolved in a 1:1 mixture of dichloromethane/methanol (12
mL total). A 0.5 M solution of methanesulfonic acid in methanol (2.37 mL) is added
dropwise to the solution. The mixture is stirred at RT for 30 min and then the solvent
is evaporated under reduced pressure. The residue is mixed with methanol and
concentrated twice to afford the title compound (0.64 g, 96%). LC-ES/MS m/z 470. 1
(M+l).
Biological Assays
The following assays demonstrate that the exemplified compounds of the
present invention are potent inhibitors of p38a MAP kinase, are potent inhibitors of
38MAP kinase, and are potent inhibitors of p38 MAP kinase signaling in cancer
cells. The following assays also demonstrate that Example 1 or salts of Example 1
(Examples 2 or 3) have potent activity in vivo, and are effective anticancer agents
either alone and/or in combination with other oncolytic agents.
Inhibition of p38a MAP kinase enzyme activity
Reagent preparation :
The kinase reaction buffer is prepared as a stock solution containing 1440 
of 1M 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid (HEPES) pH 7.5, 240 
of 1M MgCl2, 72 of 1M dithiothreitol (DTT), 25 of 10% TRITON® X-100,
43223 of H2O. The substrate mix is prepared by combining the following: 2775
ΐ kinase reaction buffer, 75.0 ΐ adenosine triphosphate (ATP) at 10 mM, 270 ΐ
EGFR peptide (Upstate Biotechnology/Millipore) at 4 mM (9.17 mg/mL) and 12.5 
P-ATP. The p38 MAP kinase enzyme stock solution is prepared by diluting 0.1
mg/mL solution of purified human p38a MAP kinase in 3000 of reaction buffer.
Stock solutions of test compounds are generated by dissolving the compounds in
100% dimethyl sulfoxide (DMSO) at 10 mM. 100 stock dilution plates are
generated by diluting 2 ΐ of 10 mM stock in 198 ΐ of 20% DMSO. 1:3 dilutions
in 20% DMSO are generated from the 100 stock using a Tecan liquid handler.
Kinase assay:
For the kinase assay, 5 ΐ of diluted compound is transferred to the reaction
plate, followed by 10 ΐ of enzyme stock solution (added using a MULTIDROP®
liquid dispenser). To start the reaction, 10 ΐ of substrate mix is added with a
MULTIDROP® and the plate is shaken for 30 seconds. Final reaction conditions are
as follows: 25 mM HEPES pH 7.5, 4.25 mM MgCl2, 1.30 mM DTT, 0.004%
TRITON® X-100, 100 ATP, 100 EGFR peptide, 11.8 nM p38a MAP kinase,
and 4% DMSO. The reaction is incubated at RT for 60 minutes and then stopped by
addition of 75 ΐ of 5% acetic acid (freshly prepared). After stopping, 100 ΐ of the
reaction mixture is transferred to a phosphocellulose filter plate (Millipore, NAPH)
that is pre-washed with 100 of 0.5% acetic acid. The reaction mixture is incubated
on the phosphocellulose plate for 30 minutes, filtered using a vacuum manifold, and
washed once with 300 and then twice with 200 of 0.5% orthophosphoric acid.
TM Following the washing steps, 80 of MICROSCTNT 20 is added and the
radioactivity counted in a Trilux MICROBETA®. IC50 values are calculated using
Activity Base software (IDBS). All exemplified compounds have an IC50 of less than
0.050 . For example, Example 1 has an IC50 = 0.003 . This assay
demonstrates that the compound of Example 1 is a potent inhibitor of p38a MAP
kinase.
Inhibition of p383 MAP kinase enzyme activity
Reagent preparation:
The kinase reaction buffer is prepared essentially as described above. The
substrate mix is prepared by combining the following: 2840 Kinase Reaction
Buffer, 15.0 L ATP at 10 mM, 125 ΐ EGFR peptide at 4 mM (9.174 mg/ml), 18.75
P-ATP. The 38MAP kinase enzyme stock solution is prepared by diluting
2.25 of a 0.57 mg/mL solution of commercial 38MAP kinase (Upstate
Biotechnology/Millipore) in 2000 of reaction buffer. Stock solutions of test
compounds are generated essentially as described above.
Kinase assay:
The kinase assay is performed essentially as described for p38a MAP kinase.
Final reaction conditions are as follows: 25 mM HEPES pH 7.5, 4.25 mM MgCi2,
1.30 mM DTT, 0.004% TRITON® X-100, 20 ATP, 65 EGFR peptide, 0.25
ng/38MAP kinase, 4% DMSO. All exemplified compounds have an IC50 of
less than 0.050 . For example, Example 1 has an IC50 = 0.007 . This assay
demonstrates that the compound of Example 1 is a potent inhibitor of 38MAP
kinase.
Inhibition of p38 MAP kinase in the cell-based assay
p38 MAP kinase inhibition in HeLa cells is assayed by measuring p-
MAPKAPK2 levels following TNFa stimulation in the presence of test compound.
Human HeLa cells (ATCC) are cultured in Dulbecco's Modification of Eagle's
Medium (DMEM media) containing 10% fetal bovine serum (FBS, GIBCO). Test
compounds are prepared in 1:3 dilution series in cell culture media with a final
DMSO concentration of 0. %. For the assay, 60,000 cells per well are plated in 100
of DMEM media containing 10% fetal bovine serum in a 96 well poly-D-lysine
plate. Cells are incubated overnight at 37 °C in a 5% CO2 incubator. The next day,
plates are inverted to dispose of media and 90 of fresh media containing either
DMSO (control wells) or the test compound dilution series is added. Plates are
incubated for 1 hour at 37 °C in the presence of 5% CO2. After 1 hour, 20 of a
100 ng/mL solution of human TNFa (made in DMEM/FBS) is added to the wells, to
give a final concentration of 18.2 ng/mL. All wells are treated with TNFa, except the
control minimum signal wells, which do not receive TNFa. Cells are incubated with
the TNFa for 15 minutes (37 °C/5% CO2) in order to stimulate phosphorylation of
MAPKAPK-2, the p38 MAP kinase substrate.
For the cELISA assay, media is removed by inverting the plate. Cells are
fixed by addition of PREFER® fixative (Anatech Ltd) for 30 minutes at RT. Cells
are washed three times for 5 minutes each time with 100 of phosphate buffered
saline (PBS) containing 0.1% TRITON® X-100 (this mixture is identified as PBST).
100 of 0.6% H2O2 in PBST is added to the cells for 15 minutes to quench the
peroxidase, followed again by washing three times for 5 minutes each time with
PBST. Cells are blocked by addition of a 5% bovine serum albumin (BSA) solution
at RT for 1 hour. Cells are washed three times for 5 minutes each time with PBST.
Cells are incubated with a 1/1000 dilution of primary antibody directed against p-
MAPKAPK-2 Thr334 (Cell Signaling) in PBST containing 5% BSA at 4 °C
overnight. Cells are washed three times for 5 minutes each time with PBST. Cells
are treated with the secondary antibody, peroxidase-conjugated anti-rabbit Ig antibody
(Amersham), at 1/1000 dilution in PBST with 5% BSA for 1 hour at RT. Cells are
washed three times for 5 minutes each time with PBST.
For detection of signal, a SUPERSIGNAL® ELISA femto kit (Pierce) is used.
Equal parts of Femto luminal/enhancer and peroxidase are mixed prior to use. 100 
of the mixture is added to each well and shaken for 1 minute using a microplate
mixer. Relative light units are determined using a Victor 1420 luminometer. Relative
IC50 values are determined using Activity Base software (IDBS). All exemplified
compounds have an IC50 of less than 0.050 . For example, Example 1 has an IC50
= 0.0016 . This assay demonstrates that the compound of Example 1 is a potent
inhibitor of p38 MAP kinase signaling in cancer cells.
In vivo target inhibition (TVTI) of p38 MAP kinase in na'ive C57BL/6 mice
rVTI of p38 MAP kinase is measured in peripheral blood mononuclear cells
(PBMCs) of mice dosed orally with test compound using a flow cytometry assay for
P-MAPKAPK2, a p38 MAP kinase substrate.
Live Phase:
Male C57BL/6 mice (6-8 weeks old) are randomized into groups of 4. Test
compound is administered by oral gavage in a 0.1 mL volume of vehicle (1%
hydroxyethyl cellulose (HEC), 0.25% TWEEN® 80, 0.05% antifoam). Control
animals are administered 0.1mL vehicle with no test compound. For single dose and
dose response studies, animals are sacrificed 2 hour post-dose. For time-course
studies, animals are sacrificed at different time-points post-dose, typically, 1, 2, 4, 6,
18 and 24 hours. Whole blood is collected in EDTA-coated tubes (AQUISEL).
Phospho-MAPKAPK2 Detection in PBMCs by Flow Cytometry:
100 mouse whole blood is added into each EDTA tube and incubated at 37
°C for 10 minutes. A mixture of three antibodies are prepared at the following
dilutions in stain/wash buffer: FITC-conjugated rat anti-mouse Ly-6G mAb (BD
Biosciences) 1:25; APC-conjugated rat anti-mouse CD1 lb mAb (BD Biosciences)
1:10; and Mouse BD Fc Block (BD Biosciences) 1:100. A stock solution of
anisomycin (Sigma) is made at a concentration of 5 mg/mL in DMSO. 15 of stock
anisomycin is aliquoted in single tubes and stored at -20 °C for single usage. On the
day of the assay, the anisomycin is diluted from stock (5 mg/mL) to 100 g/mL in
stain/wash buffer (BD). An equal volume of diluted anisomycin is mixed with the
antibody mixture.
20 of the mixture above is added into each whole blood tube, one tube
every 20 sec. The sample is incubated at 37 °C for 15 minutes in a thermomixer with
gentle shaking. Lyse/Fix buffer (BD Biosciences) is diluted 5x in water and warmed
to 37 °C. 1.6 mL of the diluted Lyse/Fix buffer (= IX working concentration) is
added into each tube, one tube every 20 sec, in the same sequence as previously.
Samples are incubated at 37 °C for 10 minutes with shaking. Cells are then spun
down at 600 x g, for 8 minutes at RT. Cells are washed once with 3 mL wash/stain
buffer, PBS and 5% decomplemented (heat-inactivated) FBS. The supernatant is
discarded carefully to avoid losing cell pellets. Anti-Phospho-MAPKAPK-2 (Thr334)
antibody (Cell Signaling Technology, clone 27B) and mouse Fc block are diluted
together in Permeabilization Medium B (Caltag) (250 x dilution for both). 200 of
diluted antibody mix is used to re-suspend the cells.
Cells are then incubated at RT for 30 minutes. 3 mL of Stain/wash buffer is
then added and cells spun down as described above. The wash is repeated with 3 mL
of stain/wash buffer. Goat F(ab')2 anti-rabbit immunoglobulin-PE Conjugate
(Biosource) is diluted in stain/wash buffer (250 x dilution). 200 of diluted
antibody is then added into each tube.
Samples are incubated at RT for 30 minutes. 3 mL of stain/wash buffer is then
added and the cells are spun down. The wash is repeated with 3 mL of stain/wash
buffer. Finally, cells are re-suspended in 250 ΐ PBS plus 1% of decomplemented
(heat-inactivated) FBS. Samples are analyzed by flow cytometry (FACScaliber, BD).
After defining the viable single cell population by side and forward scatter, the level
of P-MAPKAPK2 is measured in the monocyte population defined (gated) by
CDl lb Ly6G .
Data Analysis:
The median fluorescence intensity in the monocyte cells is analyzed to
determine the level of p-MAPKAPK2. The level of p-MAPKAPK2 (pMK2) in
anisomycin-stimulated minus unstimulated monocytes from vehicle control animals is
used to determine the signal window. Percent inhibition by test compound is
determined by using the following equation:
% inhibition = 100-[100*(stimulated pMK2- unstimulated pMK2 in compound animals)]
(stimulated pMK -unstimulated pMK2 in vehicle animals)
Using this protocol, the Threshold Efficacious Dose for 70% inhibition
(TED70) for the compound of Example 1 is 5.1 mg/kg at 2 hours post-dose. The
Threshold Efficacious Concentration for 70% inhibition (TEC70) determined by
measuring circulating compound in plasma in the same assay is 39.4 ng/niL (0.084
) at 2 hours post-dose. This assay demonstrates that the compound of Example 1
has potent activity in vivo.
In vivo inhibition of p38 MAP kinase in tumor-bearing mice
A murine xenograft model utilizing the human tumor cell line, U87MG, is
used for assessment of inhibition of p38 MAP kinase in tumors
Live phase:
Female athymic nude mice (24-26 g, Harlan) are injected subcutaneous ly in
the rear flank with 5 x 106 U87MG cells per animal. Cells are injected in a 0.2 mL
volume with a 1:1 mixture of cell culture media and BD MATRIGEL™ matrix. 7
days after implant tumors are measured using a caliper and the data recorded. Tumors
are measured twice weekly thereafter and the tumor size is recorded. When tumors
reach an average volume of approximately 250 mm3 (usually 10-15 days after
implant), animals are randomized into groups of 8-10 for treatment. Animals are then
dosed orally with 0.2 mL vehicle (1% HEC, 0.25% TWEEN® 80, 0.05% antifoam)
alone or vehicle containing test compound. 2 Hours after dosing, animals are
euthanized. The tumors are excised and processed immediately by homogenization in
a solution of 1% TRITON® X-100 with a cocktail of complete protease and
phosphatase inhibitors (Roche Standard tablets complete, EDTA-free Protease
Inhibitor Cocktail. cat# 11873580001). In addition, blood is collected in
ethylenediaminetetraacetic acid (EDTA)-coated tubes and plasma generated in a 96
well plate format for exposure analysis.
P-MAPKAPK2 assay in tumor lysates:
P-MAPKAPK2 levels in the tumor lysates are determined using a Mesoscale
Discovery (MSD) capture ELISA kit (2 Phospho-MAPKAPK-2 (Thr334)). The
concentration of protein in the lysates is determined using a BioRad DC protein assay
kit (BioRad). Protein samples from each tumor lysate are adjusted to 2 mg/mL using
a solution of 1% TRITON® X-100. For mesoscale detection of p-MAPKAPK2, 50
g of tumor lysate is added to a carbon electrode-containing 96-well plate pre-spotted
with the capture antibody (= antibody against total MAPKAPK2 protein) . The p-
MAPKAPK2 level is probed using a ruthenium-labeled anti p-MAPKAPK2 detection
antibody. Following incubation with the detection antibody, the MSD plate is washed
followed by addition of MSD read buffer. After passage of current over the electrode,
electro-chemiluminescence results in the generation of light that is quantified using
the MSD Sector 6000 instrument. For each study, percent inhibition is calculated
relative to the vehicle control group, and ANOVA (means of calculating statistical
analysis of variance) analysis performed using the JMP software package for the
determination of statistical significance. The analysis is confirmed by immunoblots in
representative studies. From this study, it is determined that the compound of
Example 1 has a TED70 for p38 MAP kinase target inhibition in tumors of 2.9 mg/kg,
and the TEC70 is 31.3 ng/mL. This data demonstrates that, for the compound of
Example 1, target inhibition potency is similar in the tumor as in the PBMCs.
Determination of in vivo efficacy in xenograft models
A2780 Xenograft Model:
Female CD1 nu/nu mice are obtained from Charles River Laboratories at
approximately 22-25 g. After 1week acclimation, 2 x 106 A2780 human ovarian
carcinoma cells are injected subcutaneous ly in the rear flank of each mouse in a 0.2
mL volume in a 1:1 mixture of cell culture media and BD MATRIGEL™ matrix.
Tumor size is monitored by caliper measurement twice per week. When the average
tumor size reaches 150 mm3, animals are randomized into groups of 10. p38 MAP
kinase inhibitor treatment is initiated after randomization. Example 2 is dosed orally
in a 0.2 mL volume of 1% HEC, 0.25% TWEEN® 80, 0.05% antifoam
(HEC/TWEEN®). The compound is dosed at doses of 1, 3, and 10 mg/kg. Dosing is
performed three times per day (TID) on a schedule of 4 days on, 3 days off. Three
cycles of dosing is performed. Tumor volume is monitored twice per week during the
dosing period, and efficacy (tumor growth inhibition) is monitored relative to a
vehicle control group (n=10 animals). At 1, 2 and 8 hours after the last p38 MAP
kinase inhibitor dose, plasma is obtained from animals to determine the circulating
levels of compound in the animals.
OPM-2 Multiple Myeloma Xenograft Model:
Female CB-17 SCID mice are obtained from Taconic at 20-22 g weight. After
acclimating for one week, mice are irradiated with a dose of 2.5 Gray. Within 24
hours following irradiation, mice are injected sub-cutaneously in the rear flank with
1.0 x 10 OPM-2 cells in a 0.2 mL volume in a 1:1 mixture of cell culture media and
BD MATRIGEL™ matrix. Tumor size is monitored by caliper measurement twice
per week. When the tumor size reaches 100-150 mm3, animals are randomized into
dose groups. Compound treatment is initiated after randomization. Example 2 is
dosed orally in a 0.2 mL volume of 1% HEC, 0.25% TWEEN® 80, 0.05% antifoam
(HEC/TWEEN®). The compound is dosed at doses of 15 and 30 mg/kg. Dosing is
performed two times per day (BID) for 28 days of treatment. Tumor volume is
monitored twice per week during the dosing period, and efficacy (tumor growth
inhibition) is monitored relative to a vehicle control group (n=10 animals).
786-0 Xenograft Model in combination with sunitinib:
Female athymic nude mice are obtained from Harlan Labs at a weight of 24-
26 g. After 1week acclimation, 5 x 106 786-0 human renal cell carcinoma cells are
injected subcutaneously in the rear flank of each mouse in a 0.2 mL volume in a 1:1
mixture of cell culture media and BD MATRIGEL™ matrix. Tumor size is
monitored by caliper measurement twice per week. When the average tumor volume
reaches 150-200 mm3, animals are randomized into groups of 8-10. p38 MAP kinase
inhibitor treatment is initiated after randomization. The compound is dosed orally in a
0.2 mL volume of 1% HEC, 0.25% TWEEN® 80, 0.05% antifoam (HEC/TWEEN®).
Dosing is performed twice per day (BID) at 15 mg/kg either alone or in combination
with 10 mg/kg or 20 mg/kg of sunitinib, also dosed orally BID in the same vehicle.
Tumor volume is monitored twice per week and efficacy (tumor growth inhibition) is
compared relative to vehicle-treated control animals.
*statistically significant compared to vehicle.
Data from this study demonstrates that p38 MAP kinase inhibition (15 mg/kg
BID) enhances the anti-tumor efficacy of sunitinib dosed at 20 mg/kg. Statistical
assessment of synergy was performed using two-way repeated measures analysis of
variance on log tumor volume vs. time. This analysis demonstrated overall significant
synergy (p> 0.0001) between 15 mg/kg BID of the p38 MAP kinase inhibitor and 20
mg/kg BID of sunitinib.
The compounds of the present invention are preferably formulated as
pharmaceutical compositions administered by a variety of routes. Most preferably,
such compositions are for oral or intravenous administration. Such pharmaceutical
compositions and processes for preparing same are well known in the art. See, e.g.,
REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY (D. Troy, et al,
eds., 1st ed., Lippincott Williams & Wilkins, 2005).
The compounds of the present invention are generally effective over a wide
dosage range. For example, dosages per day normally fall within the range of about
14-155 mg. In some instances dosage levels below the lower limit of the aforesaid
range may be more than adequate, while in other cases still larger doses may be
employed without causing any harmful side effect, and therefore the above dosage
range is not intended to limit the scope of the invention in any way. It will be
understood that the amount of the compound actually administered will be determined
by a physician, in the light of the relevant circumstances, including the condition to be
treated, the chosen route of administration, the actual compound or compounds
administered, the age, weight, and response of the individual patient, and the severity
of the patient's symptoms.
We Claim:
1. A compound of the formula:
where:
X is methoxyethyl or ethoxymethyl;
Q is cyclopropyl, 2-methyl-propanol-2-yl, 3-methyloxetan-3-yl, 1-
hydroxymethyl- 1-cyclopropyl;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 which is 2-[5-(2,4-difluorophenyl)-4-
[2-[[(lS)-3-methoxy-l-methyl-propyl]amino]oxazolo[5,4-b]pyridin-5-yl]-lHimidazol-
2-yl]-2-methyl-propan-l-ol, or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 1 or claim 2 which is crystalline 2-[5-
(2,4-difluorophenyl)-4- [2- [[( 1S)-3-methoxy- 1-methyl-propyl] amino] oxazolo[5 ,4-
b]pyridin-5-yl]-lH-imidazol-2-yl]-2-methyl-propan-l-ol characterized by the X-ray
powder diffraction pattern (Cu radiation, = 1.54060 A) comprising a peak at 15.06,
and one or more peaks at 19.94, 10.3 1, and 20.78 (2+/- 0.2°).
4. The compound according to claim 1 or claim 2 which is crystalline 2-[5-
(2,4-difluorophenyl)-4- [2- [[( 1S)-3-methoxy- 1-methyl-propyl] amino] oxazolo[5 ,4-
b]pyridin-5-yl]-lH-imidazol-2-yl]-2-methyl-propan-l-ol characterized by the X-ray
powder diffraction pattern (Cu radiation, = 1.54060 A) comprising a peak at 13.73,
and one or more peaks at 16.54, 22.87, and 18.57 (2+/- 0.2°).
5. The compound according to claim 1which is 5-[2-cyclopropyl-5-(2,4-
difluorophenyl)- lH-imidazol-4-yl]-N-[(l S)-3-methoxy- 1-methyl-propyl]oxazolo[5,4-
b]pyridin-2-amine, or a pharmaceutically acceptable salt thereof.
6. The compound according to claim 1which is 5-[5-(2,4-difluorophenyl)-2-
(3-methyloxetan-3-yl)-lH-imidazol-4-yl]-N-[(lS)-3-methoxy-l-methylpropyl]
oxazolo[5,4-b]pyridin-2-amine, or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 1which is [l-[5-(2,4-difluorophenyl)-4-
[2-[[(lS)-2-ethoxy-l-methyl-ethyl]amino]oxazolo[5,4-b]pyridin-5-yl]-lH-imidazol-2-
yl]cyclopropyl] methanol, or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising a compound or salt according to
any one of claims 1 to 7 in combination with one or more pharmaceutically acceptable
carriers, diluents or excipients.
9. The pharmaceutical composition according to claim 8 further comprising
one or more therapeutic agents.
10. A method of treating cancer in a mammal comprising administering to a
mammal in need of such treatment an effective amount of a compound or salt
according to any one of claims 1to 7 wherein the cancer is selected from ovarian
cancer and multiple myeloma.
11. The method according to claim 10 wherein the cancer is ovarian cancer.
12. The method according to claim 10 wherein the cancer is multiple
myeloma.
13. A method of treating renal cancer comprising administering to a mammal
in need of such treatment an effective amount of a compound or salt according to any
one of claims 1to 7 in combination with sunitinib.
14. The method according to claim 13 wherein the compound or salt is
administered in simultaneous, separate or sequential combination with sunitinib.
15. A compound or salt according to any one of claim 1 to 7 for use in
therapy.
16. A compound or salt according to any one of claims 1to 7 for use in the
treatment of cancer.
17. A compound or salt for use according to claim 16 wherein the cancer is
ovarian cancer.
18. A compound or salt for use according to claim 16 wherein the cancer is
multiple myeloma.
19. A compound or salt according to any one of claims 1to 7 for use in
simultaneous, separate or sequential combination with sunitinib in the treatment of
cancer.
20. A compound or salt for use according to claim 19 wherein the cancer is
renal cancer.